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Streptomyces bacteria are known to produce a large number of bioactive secondary 
metabolites. The genome sequence of the model organism Streptomyces coelicolor 
A3(2) revealed the presence of multiple previously unknown antibiotic-like gene 
clusters (Bentley et al., 2002). A transcriptional activator named MmyB was proposed 
to specifically trigger the production of the methylenomycin antibiotics in S. 
coelicolor A3(2).  S. coelicolor A3(2) itself, which encodes 16 proteins highly similar 
to MmyB (Xu et al., 2012), each of them proposed to control the expression of a 
distinct biosynthetic gene cluster or to control the expression of other uncharacterised 
genes was our main target micro-organism. (O'Rourke et al., 2009).  
The aim of this project was to clone a series of mmyB-like putative pathway-specific 
transcriptional activators under the control of a Streptomyces constitutive promoter in 
integrative vectors. These vectors were then introduced in Streptomyces bacteria, 
using intergenic conjugation. The effect of mmyB-like gene overexpression was then 
investigated by: i) analysing the expression of specific sets of antibiotic biosynthetic 
genes using RT-PCR, ii) assaying the antibiotic activity of metabolic extracts where 
mmyB-like genes were overexpressed versus negative controls and iii) To identify, 
isolate and elucidate the structure of antimicrobial using analytical chemistry (LC-MS, 
HPLC, NMR) in collaboration with analytical chemists. S. coelicolor A3(2) itself 
which encodes 16 proteins highly similar to MmyB (Xu et al., 2012), each of them 
proposed to control the expression of a distinct biosynthetic gene cluster or to control 
the expression of other uncharacterised genes was our main target micro-organism. 
This project successfully revealed that overexpression of transcriptional activators was 
a powerful strategy to discover new natural products by switching on silent 
biosynthetic gene clusters. Our understanding of the molecular mechanisms by which 
particular families of transcriptional activators function was essential in order to 
determine which specific genes within a cluster would be overexpressed and would 
result in overproduction of cryptic metabolites. 
The antibiotic activity of culture extracts and purified metabolites from engineered S. 
coelicolor strains overexpressing mmyB-like transcriptional activators was then 
assessed against Bacillus subtilis. In addition to confirming methylenomycin 
xx 
 
overproduction, these essays also revealed the production of new natural products 
(lantibiotic-derived and poly unsaturated fatty acid-derived). 
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1 Chapter 1: Introduction  
 Antibiotic history  
 
The term “antimicrobial agent” refers to the group of drugs including antibiotics, 
antivirals, antifungals and anti-protozoal agents. Antibiotics are often produced by 
microorganisms such as bacteria and fungi (Scholar and Pratt, 2000). The term 
antibiotic refers to a drug that cures infections caused by bacteria. An antibiotic has 
the ability to either kill other bacteria (bactericidal) or inhibit the growth of other 
bacteria (bacteriostatic activity) (Walsh, 2003). Antibiotics are very important and 
widely used in the prevention and treatment of infectious diseases (Bentley, 2000). 
Sir Alexander Fleming discovered the first natural antibiotic used in medicine in 1928 
in London and used during the Second World War, when he observed that the mould 
Penicillium chrysogenum produced a substance able to kill Staphylococcus sp. This is 
now known of as penicillin (Houbraken et al., 2011). Following the discovery of 
penicillin, many more antibiotics were discovered and developed rapidly. This 
resulted in an ability  to cure many infectious diseases (Fleming, 1929). 
Once antibiotics started being used regularly, resistant microbes quickly appeared due 
to incorrect and over-usage. Over-prescription and the non-exclusive usage of 
antibiotics for only bacterial infections remains a global problem in modern health 
care, as well as in agriculture (Davies et al., 2010, Fleming, 1944, Frearson and Wyatt, 
2010, Harbarth et al., 2015).  
Many scientists are still constantly searching for novel antibiotics (Wain et al., 1997). 
A potential source of novel antibiotics is Streptomyces bacteria (Procopio et al., 2012, 
Shlaes et al., 2004, Wright, 2010). 
  




Streptomyces bacteria are found naturally in the soil (Zhou et al., 2011). They belong 
to the Actinomycete class (Aigle and Corre, 2012, Anné et al., 2012, Hindra et al., 
2014, Watve et al., 2001). They are Gram- positive and characterized by the high G+C 
content in their DNA and  the erection of aerial hyphae around 0.5–2.0 µm long (Bhave 
et al., 2013).  
 
Streptomyces has a complex life cycle which starts with single spores that germinate 
with the right nutrients present, then grow and branch to form a vegetative mycelium. 
Thereafter, they will grow upright forming aerial hyphae caused by poor 
environmental conditions such as reduction in the quantity of nutrients (Flardh and 
Buttner, 2009). Later, dependence on low nutrients (such as high mineral composition, 
neutral pH) within a given growth area leads to the formation of spores enabling 
survival , the mature spores are released to start the life cycle again (Flardh and 
Buttner, 2009, Hodgson, 2000, Hopwood, 1999, Zhou et al., 2011) (Figure 1). 
 
It has been well-known that sporulation coincides with biosynthesis of antibiotics such 
as actinorhodin in Streptomyces coelicolor A3(2) (Slama et al., 2014, Watve et al., 
2001). These bacteria have the ability to produce a large number of unique bioactive 
secondary metabolites that are not essential for growth but have a wide range of 
pharmacological and agricultural applications. Examples of these antibiotics include 
streptomycin (Distler et al., 1987), chloramphenicol (Akagawa et al., 1975), 
tetracycline (Procopio et al., 2012) and neomycin (Dulmage, 1953), as well as 
antifungal agents for example nystatin (Brautaset et al., 2008), as well as anti-parasitic 
such as avermectins (Fisher and Mrozik, 1992), antitumor drug, antiviral, anti-
hypertensive and immunosuppressant agents (Demain and Vaishnav, 2011).  
  

















Figure 1: The life cycle of Streptomyces , picture adapted from (Flardh and Buttner, 2009). 
 
The first antibiotic isolated from Streptomyces species suitable for human medicine 
with a broad spectrum of activity was the aminoglycoside streptomycin. It was 
discovered by Waksman’s group. Isolated from S. griseus in 1944 and used in the 
treatment of tuberculosis. It targets and inhibits protein synthesis in Mycobacterium 
tuberculosis (Finken et al., 1993, Kincade et al., 1948, Singh and Mitchison, 1954, 
Waksman et al., 1946).  
After the discovery of streptomycin, there was a large number of newly discovered 
important antibiotics suitable for human medicine found between 1944 and 1960, also 
referred to as the “the golden age of antibiotics” (Procopio et al., 2012). Streptomyces 
species are able to produce many diverse bioactive secondary metabolites (Nett et al., 
2009). They are natural products not typically essential for growth. Some of these 
molecules provide a defence mechanism to fight other bacteria that are competing for 
resources and many can therefore be used as antibiotics (Figure 2). Approximately 
two thirds of clinically useful antibiotics originate from Streptomyces species (Kieser, 
2000, Procopio et al., 2012, Ventura et al., 2007).  












Figure 2: An example antibiotics produced by Streptomyces, the Image adapted from (Procopio et al., 
2012). 
 
Streptomyces coelicolor A3(2) has been a model organism, easily recognisable due to 
the colour  of the pigments of some compounds produced by this organism such as 
actinorhodin (blue) and prodiginines (red).  
There are five compounds that were found to be produced before its genome was 
sequenced: calcium-dependent antibiotic (CDA), grey spore pigment, prodiginines 
(Red), actinorhodin (Act), and methylenomycin (Mm) compounds (Bentley et al., 
2002, Liu et al., 2013).  
S. coelicolor A3(2) genome was one of the first sequenced bacteria published. This 
bacterium has a single linear chromosome around 8 667 507 base pairs (bps) which 
contain 72 % GC. The genome also contains two extra-chromosomal plasmids; the 
linear SCP1 around 365,000 bps which contain 69 % GC (Bentley et al., 2002, Bentley 
et al., 2004) and the circular SCP2 around 31,000 bps and contain 72 % GC (Bentley 
et al., 2002, Haug et al., 2003). The genome contains around 25 cryptic biosynthetic 
gene clusters predicted to be involved in secondary metabolite biosynthesis, many of 
the gene clusters were under further investigation but they could not be expressed in 
laboratory growth conditions and sometimes needed either an inducer molecule or 
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very specific environmental conditions to induce biosynthesis of the natural product 
by switching on the silent cryptic gene cluster (Bentley et al., 2002).  
Over the last decade genome mining approaches have been developed to discover new 
natural products and it has helped identify gene clusters by specific domain analysis 
and annotation (Aigle & Corre, 2012) more information about the genome mining can 
be found in the section (1.5 Genome mining, page 22).   
1.2.1 Methylenomycin 
 
Both Streptomyces coelicolor A3(2) and Streptomyces violaceoruber SANK 95570 
can produce methylenomycin (Chater and Bruton, 1985) but S. violaceoruber was not 
used in this study.  
1.2.1.1 Types of methylenomycins 
 
S. coelicolor A3(2) can produce methylenomycins A and C. The structures of these 
methylenomycins are illustrated in (Figure 3). These two methylenomycin antibiotics 
are natural product. Methylenomycin C is the precursor for the cyclopentanoid 
antibiotic. Methylenomycin A. Acidic shock and limiting alanine conditions were 
shown to trigger the production of methylenomycin A in S. coelicolor A3(2) but it is 
still poorly understood in terms of the mechanisms involved in responses to pH and 
heat shock (Hayes et al., 1997, Yoon and Nodwell, 2014). Methylenomycin B another 
cyclopentanoid antibiotic (not shown here) appears to derive from the decarboxylation 







Figure 3: Structure of antibiotics methylenomycin A and methylenomycin C, picture taken from 
thesis (Styles, 2016)  
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1.2.1.2 Methylenomycin Biosynthetic Gene Cluster 
 
The 19 kb mmy methylenomycin gene cluster is located on the linear plasmid SCP1 
and contains 21 genes. The genes responsible for producing the biosynthetic 
machinery needed for methylenomycin A and C synthesis form several operons; 
mmyBQEDXCAPK, mmyTOC, and mmmYF. The mmfLHP operon is responsible for 
the production of enzymes required to synthesise the five methylenomycin furan 
(MMF) signalling molecules. Also in the methylenomycin gene clusters are mmfR and 
mmyR, coding for DNA-binding transcriptional repressors, mmyJ and mmr, which are 
involved in methylenomycin resistance, and mmyB, a transcriptional activator 
methylenomycin antibiotics.(Corre et al., 2008),  
The structures of these methylenomycin gene clusters are illustrated in (Figure 4) 
(O'Rourke et al., 2009). The production of methylenomycin is dependent on the 
expression of mmyB. The MmyB activator binds to the “B-box” sequence to activate 
expression of methylenomycin biosynthetic genes. However, deletion of mmyB 
renders the bacterium incapable of producing the methylenomycin antibiotics 










Figure 4: The gene for antibiotic biosynthesis methylenomycin are clustered in S, coelicolor A3(2). 
These set of genes typically include biosynthetic genes, resistance mechanism gene and pathway-
specific transcription regulators. Picture adapted from (O'Rourke et al., 2009). 
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 Transcriptional regulation 
Transcriptional regulation is very important step for controlling gene expression. 
Streptomyces regulatory systems often include both transcriptional activators and 
repressors, signal molecules and sigma factors this can control biosynthesis gene 
cluster to final production of any natural products (Aigle and Corre, 2012, Jacob and 
Monod, 1961, O'Rourke et al., 2009). 
 
1.3.1 Transcriptional Repression 
 
Transcriptional repressors are proteins which can bind to specific nucleotide 
sequences in operator regions located near a promoter and block RNA polymerase. 
They can often inhibit their own expression (Payankaulam et al., 2010). The TetR 
family of transcriptional regulators mainly act as repressors (Cuthbertson and 
Nodwell, 2013). It was discovered in Escherichia coli regulator of resistance to the 
antibiotic tetracycline. The TetR repressor protein functions as a homodimer with each 
subunit consisting of a ligand-binding domain and an N-terminal DNA-binding 
domain (Cuthbertson and Nodwell, 2013, Ramos et al., 2005). Another example for 
TetR family member transcription repressor is MmfR and MmyR (O'Rourke et al., 
2009). 
1.3.1.1 Transcriptional Regulation by MmfR 
 
MmfR is a member of the TetR family of transcriptional repressors as is its paralogue 
MmyR. It form a homodimer with a N-terminal DNA binding region and a C-terminal 
ligand-binding domain (Chater and Bruton, 1983). Both MmyR and MmfR are similar 
in sequence to the Streptomyces griseus DNA-binding protein, ArpA the first studied 
ArpA repressor in Streptomyces (O'Rourke et al., 2009).  
MmfR shows 32% identity and 58% similarity to Streptomyces griseus DNA-binding 
protein ArpA, the first studied ArpA repressor in Streptomyces. ArpA binds to the 
promoter region of adpA, encoding the pathway-specific activator for overproduction 
streptomycin biosynthesis (Chater and Horinouchi, 2003). 
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MmfR is very important repressor of the production of methylenomycin antibiotic in 
S. coelicolor and binds to specific DNA sequence regions known as methylenomycin 
auto-regulatory response elements (MARE) in the operator region upstream of the 
mmyB gene ; in the presence of MMF, MmfR is released from the MARE sequence 
(O'Rourke et al., 2009).  
MmfR is proposed to bind to three different intergenic locations within the 
methylenomycin cluster, thereby blocking the promoters for mmfR, mmfL, mmyY, 
mmyB and mmyR cluster biosynthesis and block promoters binding to mmfR - mmfL 
and mmyY - mmyB intergenic region (O'Rourke et al., 2009). The binding of MmfR to 
the three MAREs is illustrated in (Figure 5). 
 
Figure 5: Methylenomycin gene cluster from S. coelicolor regulated by transcriptional repressors 
MmfR and focus on the areas surrounding the MAREs the image adapted from (Corre et al., 2008). 
 
1.3.1.2 Transcriptional Regulation by MmR 
 
MmR is also a TetR family member of transcriptional repressors. It has 43% identity 
and 65% similarity to MmfR (O'Rourke et al., 2009). ). In the absence of MMF 
signalling molecules, these repressors prevent expression of the transcriptional 
activator MmyB via binding to the mmyB operator, in presence of MMF, MmfR is 
released from the MARE sequence and leads to methylenomycin production. For 
example, the S. coelicolor methylenomycin overproducing strain W89 was generated 
by replacing mmyR with an apr gene (for Apramycin resistance), this confirmed that 
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MmyR represses Mm biosynthesis. Both MmyR and MmfR have been shown to bind 
to the promoter region of mmyB (Corre et al., 2010). 
 
1.3.2 Transcriptional Activators 
 
Transcriptional activators are proteins which can bind to specific sequences in a DNA 
site located near a promoter then recruit RNA polymerase that will cause stimulation 
and  transcription of nearby genes thus activating the expression of biosynthetic genes 
cluster then help to produce natural product (Barnard et al., 2004). S. coelicolor gene 
cluster often contain transcriptional activators to control the production of metabolite 
for example actII-orf4 (actinorhodin), redD (streptorubin), and mmyB 
(methylenomycin) (Aigle and Corre, 2012, O'Rourke et al., 2009).  
There are two main families of pathway-specific positive regulators that have been 
described in Streptomyces; the numbers of these regulatory genes present vary 
between BGC’s. The first is the SARP (Streptomyces Antibiotic Regulatory Proteins) 
family; these have been found in a wide variety of BGC’s, such as type I and II PKS 
clusters and non ribosomal peptide synthetize (NRPS) clusters but only in 
actinomycetes. The second family of regulators is the LAL (Large ATP-binding 
regulators of the LuxR family) family, found in both proteobacteria and widely in 
actinomycetes. (Aigle and Corre, 2012). 
1.3.2.1 Transcription regulator MmyB  
 
The MmyB protein is found in Streptomyces coelicolor A3(2). It is a proposed 
pathway specific transcriptional activator for the methylenomycin biosynthetic gene 
cluster.  
By knocking mmyB out it is hypothesised that this will prevent the expression of the 
methylenomycin biosynthetic gene cluster and subsequent production of the 
methylenomycin antibiotic (O'Rourke et al., 2009).  
A MmyB-like transcription regulator protein has been characterized and the crystal 
structure generated for MltR in Chloroflexus aurantiacus. It has an N-terminal DNA-
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binding domain and a C-terminal ligand-binding module (Xu et al., 2012) (more detail 
in page 12).  
Expression of mmyB is repressed by the transcriptional repressor MmfR but upon the 
addition of a methylenomycin furan (MMF), which is a hormonal regulatory system 
widely found in Streptomyces species (belonging to the group of 2-alkyl-4-
hydroxymethylfuran-3-carboxylic acids (AHFCAs) that are structurally distinct from 
the GBL family (Corre et al., 2008). MMF is able to make a conformational change 
of MmfR and MmR then these repressors are released from the DNA from the mmyB 
promoter site. The mmyB is able to express after the removal of repression at the 
MARE (O'Rourke et al., 2009), the resulting MmyB protein then binds to a pseudo-
palindromic sequence called the B-box (16 bps sequence which is located near mmyB 
- mmyY intergenic region and promoter of mmyT) in the methylenomycin cluster and 
help to recruit RNA polymerase then activates expression of the methylenomycin 










Figure 6: Proposed mechanism by which the pathway-specific transcription activator MmyB controls 
production of the methylenomycin (Mm) antibiotics in S. coelicolor. In absence of methylenomycin 
furan inducers, the MmfR repressor binds to a specific DNA sequence Methylenomycin Auto-
regulatory Response Element (MRAE) in the operator region upstream of the mmyB gene (1).  In 
presence of MMFs the MmfR is released from the MARE sequence and mmyB is expressed (2). The 
DNA-binding protein MmyB can then bind to B-boxes and recruit RNA polymerase thus activating the 
expression the antibiotic biosynthetic genes (3) the Image adapted from (O'Rourke et al., 2009). 
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1.3.2.1.1 MmyB homologues in S. coelicolor A3(2) 
 
S. coelicolor has 16 proteins highly similar to MmyB each of them responsible for 
controlling different pathways, these protein may be involved in promoting 
biosynthesis of other natural product (Table 1) (Xu et al., 2012). The MmyB 
alignment is reported below in Figure 7. 
 
Table 1: A Protein Blast was carried out and revealed the presence of conserved MmyB-like in S. 
coelicolor species (Xu et al., 2012). 
Protein 
names 
Percentage identify/ similarity and 
over number of amino acids 
(compared to MmyB) 
Total number of 
amino acids  
SCO2537 43/58  over 255 294 
SCO0110 37/51  over 263 297 
SCO4944 37/54  over 275 291 
SCO7706 37/50  over 257 284 
SCO0307 37/53  over 246 295 
SCO0891 36/52  over 255 279 
SCO0236 33/46  over 262 290 
SCO2501 37/54  over 234 298 
SCO7817 34/50  over 214 280 
SCO7767 32/34  over 252 275 
SCO4680 37/49  over 216 296 
SCO0233 34/44  over 252 279 
SCO7140 36/49  over 152 276 
SCO6926 29/43  over 183 274 
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SCO6926      -------mcgaikdgggegestgigallrvfraaag-ttlg-------------rp-ilq            38 
SCO0891      ------------------mtatefgralrlrrdrvspeaag----lpaggh-rraaglrr            37 
SCO4680      ------------------mkyaelgsflrsrrerirpadvg----lpagpr-rrvpglrr            37 
SCO7817      -----------------------madflrhrrealrpedvg----lspgar-rrarglrr            32 
SCO0233      -----------------midrsglaqflrhrrealqpedvg----lprgrr-rrtsglrr            38 
SCO7140      -----------------madraalaaflrarrealqpedvg----lprgrr-rrtgglrr            38 
SCO7767      ------------------mssqeladflrrrredlrpedvqaettlppsrrarrtpglrr            42 
SCO0236      ---------------mkdesgnrlgsylrarrelitpaqag----ippggn-rrvpglrr            40 
SCO7706      ------------------mddnhlgeflrarraglrpqdvn----mashgl-rrvaglrr            37 
SCO4944      --------------dgqldrraelseflrtrrarlkpedvg----lesygrqrrvpglrr            42 
SCO0307      -------------------msselgdflkarrrelspptag----lpadgr-rrvpglrr            36 
SCO0110      --------------mptntnraelrdflrsrrarvspedvg----ipatv-rrrtpglrr            41 
SCO2501      mtgretavqspprdtgseirrhelaaflrsrreriapeqvg----lprgr-rrrtpglrr            55 
MmyB         -masvdgvakdstvcspkrqrealrhflrsrrarlspddvg----llatg-rrhtpglrr            54 
SCO2537      -------mitragtagrdrrrselreflmsrrarvspaevg----lpdggarrrtpglrr            49 
                                    :   *   *                         : : 
 
SCO6926      revadalhrserwyrdleggvitrpltrheldtigtllgldrvqrralflvsnggglssp             98 
SCO0891      eelallagisvdyvtrleqgraanps-aqvvealvralrlpaeerahlfrlaglapp-gp 95 
SCO4680      eevahlagasvdyynelergagsqps-eqmlaalaralrlsaderdylyrladrpvp-vp 95 
SCO7817      eevaalalmstdyytrleqrrgpqps-ermldslaralrltraerdylyrvaghnap-as 90 
SCO0233      eevaalchmstdyyarlerergpqps-qqmivsiaqglhlslderdhlfrlaghtpp-pr 96 
SCO7140      eevaalcdmsvdyysrleqprgphps-eqmltsmarglrlsleerdllfqlaghalp-rr 96 
SCO7767      eevaalaqvsvsyyerleqaraprps-pqvlsalatalqltdaerdhlarlagqvlp-ae      100 
SCO0236      eevallagispdyylrlergrdknps-pqvleslarvlqlddiertyllglaaarpr-ap             98 
SCO7706      eevavlagvnadyytrleqgrerhps-pqvldalgralrldpearahlhrlagvspa-gr 95 
SCO4944      eelaqlagvsvayytrleqgngqnvs-aevldaiaralrltdaeqahlthlarpkqq-rr        100 
SCO0307      eevavlasispghytrleqgrrr-as-epvldalaralrlsaderaylfelsgkdag-rp 93 
SCO0110      eevaqlagvgitwytwleqgrpinvs-sqvldavartlildaaerdhlyrlaevpqp-pv 99 
SCO2501      eevaqlsavgvtwytwleqardiqvs-vqvldalartllldpterahlfqlagsvdp-tp         113 
MmyB            eevaviagvsaswytwleqgrdikvs-dgvlnaisqalrlddterahlyrlagvnpp-qs     112 
SCO2537      eevavlagvgaswyqwleqgrdisvs-pqvldavgrvlrlsnterrhlyvlaglnpp-aa     107 
             .*:*     .      **            : ::   * *    :  *  ::         
 
SCO6926      e---tqepprisde-lrllldqqpfpayvidatwnvlavntsmaalfpwst---apganl         151 
SCO0891      e----avpayippsvhrlldrlagtpvavydamwtlllanppyaalmgdpsewhgperng  151 
SCO4680      g----gpashvhpgmldllgrmtstpaqvitdlhvtlvqnplavallgdqsgyrgprasf       151 
SCO7817      l----sdpspvapallrvldrlddtpaliltelgetlvqnrmavalfgdasrhtglarsa           146 
SCO0233      g----tdgehispgllrildrlddtpaeivtelgetlrqtrlgialtgdqtrysgparsi           152 
SCO7140      a----rrgdhvapgtmrildrledtpaqvmnhlgetlsqtrpamtllgdqtaytglarss         152 
SCO7767      n---dgtpehvpedaqqllgrldgipayivndrqdivawnaaaaalitdfsrltpdernl        157 
SCO0236      r---rkrpehvparvhell-ahlpipafvegrafdvlasnpmavalsprlrp----gqnr          150 
SCO7706      d--slhatervgpalrqlmdgyahtpafvmsrtldvlaanaladalyapftp----adnl        149 
SCO4944      ragaargkqpvrvallqlldsidtvpayvsgrrseilawnrmaaalfgdwgklpaaernw   160 
SCO0307      l---grpgrqvrpqlrrllddlthtpalvlgrctdilawnppaaalftdfallsrdernf           150 
SCO0110      i--sdppt-elpghldtvlealdplpamlvdartdvlrwnrayaalhpalvsappgkrnt       156 
SCO2501      a--tdcpa-itp-avralleqfepypacvqnsrydilahnrtyglllcdldavppedrnc         169 
MmyB            v--patagqtetsrlqlivdgwlpapafvvdrywntlaanqaars---algvgag-dqny     166 
SCO2537      e--vepskrdmceglrrlidtwmpypahimdryyncvlyndaaat---vlgmrpettwnc  162 
                              ::      *. :       :  .                  .  
 
  




SCO6926      mrwlllsae--ardqhlhweadaevcvcmlrdaavdrp-hdpdlqqlisds-rqnpavrd  207 
SCO0891      vwrnfvgpgsrarytpgerrsfesalvadlrataaryp-adrrlgrlvaelrarserfae         210 
SCO4680      vhrwftepearllypeadhayqsrsfvadlraaaarrdakdteagamvrtllgvspefaa    211 
SCO7817      vyrwftdpsersvypesdwgrqsraqvanlraaygmrg-arshagalvrilqqsneefae 205 
SCO0233      gyrwftdpatrqlyhpddhafltrmfasglrevatlrg-pgsraahyadlllaqseefrr         211 
SCO7140      hyrwftdpaarlvhpasdhaeqsrlmvadlhsaysrdg-gdsgaaalvdalnrespefag211 
SCO7767      tristrfrgtlctgapgsesefsqqvaaqlraasvlyp-tdkvlaelinefathdpdfas           216 
SCO0236      lrdllldpe--eqefhqdwpkatadfvaalrttigddt-dnprfvelvgelslssqrfrt           207 
SCO7706      armifldpa--grefyqewdraaqavvadlrqahgfdp-ehprlrrlvdtltehsavfr         206 
SCO4944      arlvflnpd--yrelfvdwdqkaydmvsflrmdagrhp-ddprlsalvgelsvkseefrr      217 
SCO0307      vrlvfrdpa--vralytdwpymaracvaqlrmeaardp-hdprlsalvaelsaqdpdfrt     207 
SCO0110      lwqlfaape--gqprivnrdeqapeavagfryrysqna-gdprwqdfvarlrtasplfsr      213 
SCO2501      mvlcfthed--wrssivhleetqrlmaarfratmaghl-aepawkmllkrlrtqspafre       226 
MmyB         laafftept--araryldwdklatrlvgqfrvqaarfp-edprfdriarqlcatdhafad           223 
SCO2537      ildfftdpl--yrsrarnwehnartvvaqfratcaanp-ddegfqqvladltgasaefaa        219 
                                       .  ::                       .  .   
 
SCO6926      lwtrgaadfadhydghvlqmtlplfdgqvtelvthvlqpaglpgcrmtiltqrapqepsg      267 
SCO0891      lwradavgrheaarktidhprvgpv-----vldcdvlgva-gsdlrimvytaepdtadae     264 
SCO4680      lwadhdvafrrhdrkrlvhpviglv-----evnclnlfse-dgrqrllwftpavgtesag           265 
SCO7817      lwerhevaqrfedhktlihpevgai-----evdcqalfte-dqsqtllvltapprteshe           259 
SCO0233      vwkehtvgirpkevkhfvhpevgal-----eltcqtlldp-sqahmllvytatpggesye       265 
SCO7140      lwrqrpvlgpycaskrfvhpqvgtl-----elhcqtlidp-dhgqrlvvytatpgtesht           265 
SCO7767      swrnhavrpipgvrkrlhhptlgel-----eidrhtlslp-gsgfslvmytaevgspsaa         270 
SCO0236      lwarhevrsldggsttvhhpvvgdl-----hlhrdklpve---dvilvvyypdkdsdsde       259 
SCO7706      lwaehsvrgktqdakrllhpdvgtl-----sltyqsfdvrdapgqqlviyhaepgspsah      261 
SCO4944      lwathdvkeksygvkrmrhplvgdl-----tlsfetfrlvdddeqafityhaepgspsad       272 
SCO0307      wwkdhrvavrgagtkdlrhpvigel-----tldwsaltdtadpdqqlialtaapgtpshd       262 
SCO0110      lwtthdvapphlcdkryditgigev-----slratsmeltdhpgvrlvvqtpadrrsren         268 
SCO2501      awerhevvahrgkrkeflnrhvgri-----rvdhtdlwlgpepgprmvtyapadedsrer    281 
MmyB         lwarhetcdtamtsvrvrppgeesm-----rfehlilallenadlrlmlymprgahisae          278 
SCO2537      lweerdiedagqirkeldhplvgll-----slestalqvparpdltivlhtpleeant-a           273 
              *                      .      .    :         :              
 
SCO6926      rq---------------------------------pvqat---              274 
SCO0891      rlalltvlgtqelve----------------------------                                              279 
SCO4680      llellsvvgtqevsevsaatrtagsstrrqg------------                                  296 
SCO7817      klqllavlglhrfteaedqvr----------------------                         280 
SCO0233      klqllsvigaqtlr-----------------------------                         279 
SCO7140      nlrllsllpvs--------------------------------              276 
SCO7767      alksl--------------------------------------              275 
SCO0236      klrllaglshsesagtprsgsstggrppqee------------             290 
SCO7706      algllgslhagerr---qgasdsagn-----------------             284 
SCO4944      alrllaswgtdaaaslpa-------------------------              290 
SCO0307      glralrdlgavtsgrtgpgvpggggeiagasaq----------             295 
SCO0110      idrllrqathl--------------------------------                   279 
SCO2501      lerlhaialer--epaasg------------------------              298 
MmyB         ag------lrl--vpadpltrnsllqlpgrpmtsrpverhihp                                  313 
SCO2537      ak------lew--laspegrrgamypvag--------------                                  294 
                                                         
Figure 7: Amino acid sequence alignment of MmyB-like proteins from S. coelicolor  




1.3.2.1.2 Structure of MmyB-like transcription regulator (MltR) 
 
The structure of the MmyB-like transcription regulator (MltR) has been discovered in 
Chloroflexus aurantiacus which is a Gram-negative bactrium. It is homolog of the 
methylenomycin activator MmyB. The crystal structure of transcriptional regulator 
MltR has been determined by X-ray crystallography and has been shown to form a 
complex with fatty acid (meristic acid). MltR consists of (Xenobiotic Response 
Element) Xre-type N-terminal DNA-binding domain and a C-terminal ligand-binding 














Figure 8: Structure of the MmyB-like transcription regulator (MltR) from Chloroflexus aurantiacus. 
(Xu et al., 2012) (A) 
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 Natural products 
The story of bioactive natural products started more than 80 years ago. Natural 
products refer to chemical compounds or is any substance that derived from the living 
organisms such as plants, animals and microorganisms which able to inhibit the 
growth bacteria and even to destroy other microorganisms (Berdy, 2005).  
Natural products, which are also called bioactive secondary metabolites, are known to 
include a wide range of antibiotic and they are not essential for bacteria growth 
(Procopio et al., 2012).  
It is important to note that not all organisms produce their full range of clinically useful 
natural products and secondary metabolites under lab conditions. (Bibb, 2005, van 
Wezel and McDowall, 2011). Only a few organism produce substances that are useful 
in research, these are known as producers. A number of them have been used to 
develop new drugs to combat infection diseases and cancer. Apart from their 
application in medicine, the natural products have also been used in the agricultural 
sector (Clark et al., 2013).  
Natural products can be developed synthetically to produce more useful product with 
less toxic effects. Normally some bacteria can switch on the biosynthesis of secondary 
metabolites that they need in response to specific extracellular stimuli normally not 
present in laboratory conditions such as particular environmental conditions or inducer 
molecules for natural product biosynthesis to be switched on (van Wezel and 
McDowall, 2011, Zhu et al., 2014). 
 So it is very important to understand the regulation of a gene cluster order to carry out 
its genetically manipulation or introduction it into a heterologous expression host 
(Gomez-Escribano et al., 2014) Some of the best sources of antimicrobial agents are 
secondary metabolites produced by Streptomyces. The new strategies for the isolation 
of new natural products are described in the (Figure 9) (Aigle and Corre, 2012).  
  











Figure 9: New natural product discovery relies on, heterologous expression of putative biosynthetic 
gene cluster in heterologous hosts (A). The biosynthetic gene cluster responsible for not producing the 
novel natural compound can be confirmed by inactivation the essential gene within the biosynthetic 
pathway (B). Inactivation of repressor gene enables the switching on silent natural products gene 
clusters (C), in addition, adding transcriptional activators can activate silent natural product gene 
clusters (D) Image adapted from (Aigle and Corre, 2012). 
 
 Genome mining  
Genome mining is important to study because there are a lot more useful natural 
products yet to be discovered (Lerner et al., 2007). Genome mining refers to searching 
an organisms genome for genes that encode enzymes thought to be involved in the 
biosynthesis of natural products, often via the comparison to known motifs from 
homologous proteins in other organisms (Challis, 2008). 
Computational software methods are rapidly advancing as an approach for annotation 
of genomic data (Weber et al., 2016) Examples of online resources includes the widely 
used the Antibiotics and Secondary Metabolite Analysis SHell (antiSMASH) (Blin et 
al., 2017, Weber et al., 2015). These resources are also useful for novel natural product 
discovery. Bioinformatic tools such as National Centre for Biotechnology Information 
(NCBI) BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) are used to compare known 
motifs from homologous proteins from different organisms. Genome sequences can 
also be analysed by using bioinformatics tools to identify the biosynthetic gene 
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Nowadays, tools like antiSMASH and BLAST could be used to technically identify 
whole biosynthetic gene clusters the for analysis of secondary metabolites (Blin et al., 
2013, Medema et al., 2013).  
Bacterial genome mining has revealed a vast untapped reservoir of novel bioactive 
products (Bentley et al., 2002). Numerous cryptic gene clusters predicted to direct the 
biosynthesis of novel natural products, in particular antibiotic, have indeed be 
identified in the genome Streptomyces bacteria (Corre et al., 2008). However under 
laboratory conditions, many of these cryptic gene clusters are not expressed, it needs 
very specific environmental conditions necessary to activate the production of the 
compounds (Corre and Challis, 2007). Hence a new approach for antibiotic discovery 
that aims to overcome these challenges can be developed by exploiting pathway-
specific transcriptional activators (Laureti et al., 2011). Genome sequence analysis has 
facilitated the identification of additional BGC’s that were previously unknown; these 
include those encoding non-ribosomal peptide synthetises (NRPSs), polyketide 
synthases (PKSs) and terpene synthases (Rutledge and Challis, 2015). 
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 Hypothesis statement 
The main hypothesis of this project as follow: 
 Could we turn on silent biosynthetic pathways by overexpressing mmyB and 
mmyB-like genes? 
 Would this novel strategy result in the overproduction and discovery of new 
natural products? 
 Aims 
 To clone mmyB and a series of S. coelicolor mmyB-like pathway-specific 
transcriptional activators under the control of a Streptomyces constitutive 
promoter. 
 
 To introduce these vectors, using intergenic conjugation in Streptomyces 
coelicolor. 
 
 To analyse the expression profile of mmyB-like genes and that of putative 
biosynthetic genes located next to the mmyB-like regulatory genes using RT-
PCR. 
 
 To test the antibiotic activity of metabolic extracts where mmyB-like genes 
have been overexpressed versus negative controls. 
 
 In collaboration with colleague to compare the metabolic profiles of the 
engineered Streptomyces strain using LC-MS analyses and possibly isolate and 
elucidate the structure of novel antimicrobials using additional analytical 
chemistry techniques (mass spectrometry and NMR spectroscopy). 
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2 Chapter 2 Materials and Methods 
 Materials  
2.1.1 Microbial strains 
 
Table 2: list of microbial strain used in this study 
 
Strain Uses/ Genotype Source 
Escherichia coli DH5α General cloning host. 
fhuA2 lac(del)U169 phoA 
glnV44 80’ lacZ(del)M15 
gyrA96 recA1 relA1 endA1 thi-




Escherichia coli Top10  Strain used in antimicrobial 
assay General cloning host. 
F- mcrA Δ(mrr- hsdRMS-
mcrBC) 80dlacZΔM15 
ΔlacX74 nupG recA1 
araD139 Δ(ara, leu)7697 






Non- methylating host for the 
transfer of DNA into 
Streptomyces species. 
ET12567: dam- dcm- hsdS cat tet 
pUZ8002 plasmid: tra neo RP4 
JIC, Norwich, UK 
S. coelicolor W81 SCP1 was deleted mmyLPH C. Corre group  
S. coelicolor+pJH2 mmyB ligated in pOSV556 
integrated in S. coelicolor W81 
Generated in this 
project 
S. albus+pJH2 mmyB ligated in pOSV556 
integrated in S. albus 
Generated in this 
project 
S. xanthocidicus+pJH2 mmyB ligated in pOSV556 
integrated in   S. xanthocidicus 
Generated in this 
project 
S. coelicolor M145 S. coelicolor SCP1-, SCP2 - JIC, Norwich, UK 
 
S. coelicolor M145+pJT1 sco6926 ligated in pOSV556 
integrated in S. coelicolor M145 
Generated in this 
project 
S. albus+pJT1 sco6926 ligated in pOSV556 
integrated in S. albus 
Generated in this 
project 
S. xanthocidicus+pJT1 sco6926 ligated in pOSV556 
integrated in S. xanthocidicus 
Generated in this 
project 





sco0110 ligated in pOSV556 
integrated in S. coelicolor M145 
Generated in this 
project 
   
S. albus M145+pVN3 sco0110 ligated in pOSV556 
integrated in S. albus 




sco7140 ligated in pOSV556 
integrated in  S. coelicolor M145 
Generated in this 
project 
S. albus M145+pHAM3 sco7140 ligated in pOSV556 
integrated in  S. albus  
Generated in this 
project 
S. xanthocidicus+pHAM3 sco7140 ligated in pOSV556 
integrated in S.  xanthocidicus 




sco7706 ligated in pOSV556 
integrated in  S. coelicolor M145 
Generated in this 
project 
S.  albus +pNBH3 sco7706 ligated in pOSV556 
integrated in  S. albus 
Generated in this 
project 
S. xanthocidicus+pNBH3 sco7706 ligated in pOSV556 
integrated in S.  xanthocidicus 




sco0236 ligated in pOSV556 
integrated in  S. coelicolor M145 
Generated in this 
project 
S.  albus +pWAL3 sco0236 ligated in pOSV556 
integrated in S. albus 
Generated in this 
project 
S. xanthocidicus+pWAL3 sco0236 ligated in pOSV556 
integrated in S.  xanthocidicus 




sco7817 ligated in pOSV556 
integrated in S. coelicolor M145 
Generated in this 
project 
S.  albus M145+pAMR3 sco7817 ligated in pOSV556 
integrated in  S. albus 
Generated in this 
project 
S. xanthocidicus+pAMR3 sco7817 ligated in pOSV556 
integrated in S.  xanthocidicus 




sco4680 ligated in pOSV556 
integrated in S. coelicolor M145 
Generated in this 
project 
S.  albus M145+pAML3 sco4680 ligated in pOSV556 
integrated in S. albus 
Generated in this 
project 
S. xanthocidicus+pAML3 sco4680 ligated in pOSV556 
integrated in S. xanthocidicus 
Generated in this 
project 





Coventry, UK  











Table 3: plasmids used in this study 
Plasmids Properties Source 





pJH2 (pC-0015) mmyB gene ligated in 
pOSV556,cloned into the HindIII 
and PstI sites. 
This study 
pJT1 (pC-0016) sco6926 gene ligated in pOSV556, 
cloned into the HindIII and PstI 
sites. 
This study 
pVN3 (pC-0017) sco0110 gene ligated in pOSV556, 





sco0236 gene ligated in pOSV556, 
cloned into the HindIII and PstI 
sites. 
This study 
pNBH3 (pC-0019) sco7706 gene ligated in pOSV556, 





sco7140 gene ligated in pOSV556, 





sco7817 gene ligated in pOSV556, 
cloned into the HindIII and stu1 
sites. 
This study 
pAML3 (pC-0022) sco4680 gene ligated in pOSV556, 
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2.1.3 Primers  
The primers were provided at stock concentration of 100 pmol/µl. Primers were then 
diluted to a final concentration of 100 mM with sterile dH2O and stored at -20 ⁰C. 








Restrictions enzyme HindIII and Pst1: Red colour and Stu1 green 
colour. Extra nucleotides: under line. Ribosome binding side 
(RBS): orange colour. mmyB, sco0110 and sco6926 genes and 






















































T09 sco7817 F: ACTAAGCTTAAAGGAGGATGGCCGACTTCCTGCGC 






















Gene name Primers sequences  5’ to 3’ 
H01 mmyB 
 
F  CAAAGATTCGACGGTGTGCA 
R  GATGACTGCGACTTCCTCAC 
H02 mmyO F  GATTCGGTGCTTTCCTCTCC 
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Primers sequences  5’ to 3’ 
 
R01 sco0108 F: ATCAAGGTCCAGTGGCTCG 
R: GCAGAGCTTTCAAGGACACC 
R02 sco0110  F: GTGCCGACAAACACGAACC 
R: GCATCCAGAATCAGCGTACG 
R03 sco0117 F: ATGGAACTGAAGAACGCGGT 
R: CCGCGTTGTTGATCAGAAGT 
R04 sco0124 F: CTGTTACGTCGTCTGCTCG 
R: GTCTCCACCACCCTCAGC 




Table 7: primers for lantibiotic genes used in RT-PCR 
Primers 
number  
Gene name Primers sequences  5’ to 3’ 
 
B01 sco6926 F: CCAGGA CCCAGACCTTCAG 
R: TGGGTCAGGATCGTCATGC 
B02 sco6927 F: ATGGACGTCGGCCAGATAG 
R: CTTGTTCAGGGCGACGGT 
B03 sco6932 F: ATGCAGAACGACGAATTCCG 
R: TCAGGCCACGTTGGTG 
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2.1.4 Molecular microbiology material used  
 
Table 8: Materials used 
supplier Material 
Fermentas Spectra™ Multicolor Low Range Protein 
Ladder 
GE Healthcare Ni Sepharose™ 6 Fast Flow  
Invitrogen Quick Gel Extraction and PCR purification 
combo kit. 
T4 DNA ligase 
New England Biolabs (UK) NEB 5-alpha Competent Escherichia coli 
HindIII and PstI 
Roche Diagnostics Expand High Fidelity PCR System 
Sigma Aldrich Primers 
Antibiotics; apramycin, ampicillin, 
kanamycin and chloramphenicol 
Thermo Fisher Scientific - 
Fermentas 
FastRuler DNA ladders 
GeneJET Plasmid Miniprep kit 
Phusion High Fidelity DNA polymerase 
Restriction enzymes and buffers 
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2.1.5 Equipment used  
 
Table 9: Equipment used 
Supplier Equipment 
Name Type 
Beckman Coulter Centrifuge Avanti j-25 
Bio-Rad 
Laboratories Ltd 





Cell, 1.0 mm gel 








Fisher Scientific pH meter 
NanoDrop 
Acument basic AB15 
NanoDrop 2000 
Spectrophotometer 
Grant Water bath JB1 
Greiner Bio-One Ltd White tissue culture 96-well 
plates 
Polystyrene, sterile 
Hettich Centrifuge Rotina 46R 
INFORS HT Incubator shaker Multitron 
New Brunswick 
Scientific 
Incubator shaker C24 
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2.1.6 Buffer recipes  
 
Buffers for preparation of competent cells: 
 
TfbI solution        30 mM K-acetate 
                     50 mM MnCl2 
                     100 mM KCl 
                     10 mM CaCl2 
                     15% glycerol 
                     pH 7.4 
 
TfbII solution        10 mM Na-MOPS 
                     75 mM CaCl2 
                     10 mM KCl 
                     15% glycerol 
                     pH 7.4  




Table 10: Media used  
LB media LB agar 
10 g tryptone 
5 g yeast extract 
10 g NaCl 
Make up to 1 L with distilled water  
pH  7.0 
 
Mix together and then autoclave 
10 g tryptone 
5 g yeast extract 
10 g NaCl 
15 g agar 
Make up to 1 L with distilled  
pH  7.0 
Mix together and then autoclave 




SMM agar (Supplemented minimal 
media) 
SMM broth (Supplemented minimal 
media) 
2 g Casaminoacids 
5.73 g TS Buffer  
15 g Bacto- agar  
1000 mL distilled water  
pH=7.2 
 
2 g Casaminoacids 
5.73 g TS Buffer  
1000 mL distilled water  
pH=7.2 
 
Add the following after autoclaving 
per litter 
10 mL NaH2 PO4 + K2HPO4 
5 mL Mg SO4  
18 mL glucose  
1 mL trace element solution 
trace element solution 
0.1 g ZnSO4 
0.1 g FeSO4 
0.1 g MnCl2 
0.05g CaCl2 
0.1 g NaCl 





SFM (soya flour mannitol) 2XYT broth 
400 mL tap water 
8 g bacto-agar 
8 g soya flour 
8 g mannitol 
Mix together and then autoclave 
16 g tryptone 
10 g yeast extract 
5 g NaCl 
1 L water 
Mix and autoclave 
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2.1.8 Antibiotics solution   
 
All antibiotics has been filtered before using then stored in 4 oC 
Table 11: List of antibiotics solution used in this project 
Antibiotics Stock Solution 
(mg/mL) 
E. coli (μg/mL) Streptomyces 
(μg/mL) 
Ampicillin 100 100 - 
Chloramphenicol 25 25 - 
Hygromycin 50 - 100 
Kanamycin 50 50 - 
Nalidixic Acid 25 25 - 
 
 Methods  
2.2.1 Molecular biology methods 
2.2.1.1 Isolation and purification of plasmids  
 
E. coli DH5α glycerol stocks were plated on Lysogeny Broth (LB) plates with 
ampicillin selection (100 µg/mL) and incubated overnight at 37 oC. Single colonies 
were selected and incubated in 10 mL LB with ampicillin (100 µg/mL) as overnight 
cultures. The vector pOSV556 was isolated using a Gene JET plasmid mini-prep kit 
(Thermo Scientific United Kingdom) according to the supplier sinstructions with some 
modification, as described below. The overnight LB cultures were centrifuged for 10 
minutes at 4000 rpm at 4 OC. The supernatant was discarded and the pellet re-
suspended in 250 µL cell re-suspension solution (CRS) and vortex mixed until 
completely re-suspended. 250 µL of cell lysis solution (CLS) was added thereafter and 
mixed by inverting the tube 4 – 6 times (not vortex mixing), before leaving the solution 
to incubate at room temperature for 2 - 3 minutes. 350 µL of neutralisation solution 
(NSB) was added and mixed with inverting the tube 4 – 6 times followed by 
centrifugation at 15,000 rpm for 5 minutes at 4 OC. The supernatant was transferred 
onto the spin column (provided in the kit) and centrifuged for 60 second at 8,000 rpm 
at 4 oC. The flow through was discarded and column washed with 550 µL of washing 
buffer (include ethanol), by centrifugation at 8,000 rpm for 60 second at 4 OC thereafter 
discarding the flow through. This washing was repeated twice and the column placed 
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in a flow cabinet to evaporate off any remaining ethanol. The plasmid was eluted from 
the column into a new sterile micro-tube with 50 - 55 µL of 65 oC filtered sterile 
distilled water then centrifuging the column at 15,000 rpm for 120 second. A 
NanoDrop ND-2000 spectrophotometer (Thermo Scientific United Kingdom) was 
used to measure the concentration of the purified plasmid. 
2.2.1.2 Agarose gel electrophoresis 
 
DNA sample were analysed on 1% agarose gels (AGTC Bioproducts) prepared in 1x 
Tris- Acetate electrophoresis buffer (TAE) with 5 µL of red gel solution per 100 mL 
gel. 5 µl DNA sample was mixed with 1 µL from 6x MassRuler DNA loading Dye 
(Thermo Scientific United Kingdom) before loading in the gel. The gel was then 
analysed bynelectrophoresis at 100 V for 40 minutes. The DNA size was compared 
relative to a FastRuler high or middle range DNA ladders (Thermo Scientific United 
Kingdom). The gels were then visualised with ultraviolet light. 
2.2.1.3 Polymerase Chain Reaction (PCR) 
 
PCR was used to amplify the DNA target sequence of gene using two primers:  
1. Forward  primers ‘mmyB, sco6926 and sco0110 were designed  with the 
restriction enzyme HindIII sequence,  
2. Revers primers ‘mmyB, sco6926 and sco0110 were designed with the 
restriction enzyme PstI sequence. Also other mmyB-like genes see (Table 4). 
 
The master mix for PCR reaction consisted of a NEB Phusion High Fidelity 
Polymerase and a fixed molar concentration of MgCl2 in Phusion High Fidelity buffer 
5x (include 15mM MgCl2) and 10 mM dNTPs are required for DNA template 
synthesis (Table 12). The reaction was 30 cycles, to gain the amplification of DNA 
target sequence, run into an automated thermal cycler following the steps reported in 
Table 13. 
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Table 12: Components and volumes used for PCR reaction to amplify the DNA target. 
Component Volume 
High fidelity phusion buffer  (5x) 10 μL 
dNTP mix. (10 mM) 1 μL 
Primer forward-HindIII 1 μL 
Primer reverse –PstI or using Stu1 1 μL 
Templet (100 ng/µL) 0.5 mL 
Dimethyl sulfoxide (DMSO) (100 %) 2.5 μL 
Phusion High Fidelity-DNA Polymerase 
(5U/μL) 
1 μL 
 Sterile distilled water up to 50 μL 34 μL 
Total 50 μL 
 
Table 13: PCR cycling programme used. 
Cycle Temperature  Time Total cycles 
Initial denaturation 98 oC 2 minutes  
Denaturation 98  oC 45 seconds  
30 cycles Annealing 55 oC 45 seconds 
Extending 72 oC 1 minute 
Final extending 72 oC 15 minutes  
Cooling down 4 oC ∞  
 
2.2.1.4 Purification of amplification products from the agarose gel 
 
The PCR amplified band on an agarose gel was purified by using the GeneJET gel 
extraction kit (Thermo Scientific United Kingdom). After cutting the DNA band of 
Chapter 2 Materials and Methods 
32 
 
interest under UV-light with a clean and sharp scalpel, the sliced gel is weighed. The 
protocol was then followed as outlined in the manufacturer`s protocol. 
2.2.1.5 Restriction enzymes used to digest both vector and gene of interest 
 
Both purified gene products and plasmids were digested separately using the 
restriction enzymes HindIII and PstI in two steps, (Thermo Scientific United 
Kingdom) as follows using supplier instructions with some modification 
First step: The construct were digested by incubating 1 µL restriction enzyme HindIII 
with 1 μg of substrate DNA and 5 µL of the relevant 10 x buffers. Sterile distilled 
water was added up to 50 µL before incubation of digestion mix for 2 hours at 37 °C 
singly digested plasmid and gene were then purified by using Quick Gel Extraction 
and PCR purification combo kit (Invitrogen) protocol as outline below: 
Add 4 volumes of binding buffer (B2) with isopropanol to 1 volume of the samples. 
Mix well then transferred into a spin column which has the filter called PureLink spin 
column filter (provided by the kit) and centrifuged for 60 second for 4000 rpm at 4 oC 
discard the flow through and place the column in the same wash tube  and  wash with 
650 µL of washing buffer (W1) (containing ethanol) before centrifuged again at 4000 
rpm for 60 second at 4 OC, discard the flow through and place the column in the same 
wash tube, then centrifuged again for 10000 rpm for 60 second at 4 OC to remove any 
remaining ethanol, discard the flow through then leave the filter spin column fume 
hood for 5 - 10 minutes to dry all the ethanol , the plasmid and gene was eluted in 
clean  micro tube by added 30 - 35 µL of 60 oC filtered sterile distilled water then 
centrifuged at maximum speed (15000 rpm) for 120 second. NanoDrop ND-2000 
spectrophotometer (Thermos Scientific United Kingdom) was used to measure the 
concentration of the cloning and purified plasmid and gene.  
Second step: Double digestion was achieved by incubating 1 µL restriction enzyme 
PstI with 1 μg of singly digested and purified DNA and 5 µL of the relevant 10x 
buffers (New England Biolabs). Sterile distilled water was again added up to 50 µL 
before incubation of digests for 2 hours at 37 °C. Plasmid and gene were purified by 
using Quick Gel Extraction and PCR purification combo kit (As previously described). 
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NanoDrop ND-2000 spectrophotometer (Thermo Scientific United Kingdom) was 
used to measure the concentration of the plasmid and gene. 
2.2.1.6 Ligation of plasmid and gene by using T4 DNA ligase 
 
After restriction digestion of plasmid and gene the ends were ligated using a molar 
ratio of 1:3 vector to insert for the indicated DNA sizes. The ligation calculator was 
used web site NEBio (https://nebiocalculator.neb.com/#!/ligation).  
Expanded Formula (required mass insert (g) = desired insert/vector molar ratio x mass 
of vector (g) x ratio of insert to vector lengths). 
This reaction was performed by using T4 DNA Ligase (400 u/µL Invitrogen) (Table 
14). Keep the micro tube incubation overnight at 16 oC. Followed by the 
transformation of plasmid in E. coli TOP 10.The resultant vector harbouring the gene 
of interest was named as pJH2, pJT1 and pVN3. 
Table 14: Components and volumes were used for ligation between pOSV556 and gene 
Components Volumes 
pOSV556 6 µL 
Gene interest  2 µL 
5x T4 ligase buffer 2 µL 
T4 1.5 µL 
Distilled water up to 20 µL 8.5 µL 
 
2.2.1.7 RNA extraction and purification 
 
Total RNA was extracted from both Streptomyces coelicolor and Streptomyces 
coelicolor with integrated genes (pHJ2, pJT1 and pVN3) grown in MMS until the 
optical density at 600 nm (OD600) reached at 1.0 (Van Dessel et al., 2004) using the 
hot acid-phenol method  with some modification (Gilbert et al., 2000). For RNA work, 
all plastic ware, tips, micro-tube, PCR tubes, pipette tips etc were used RNase-free. 
The cultures were harvested in RNase free Falcon tubes, centrifuged for 5 minutes at 
3500 rpm at 4 OC. The supernatant was kept for antibiotic assay and the pellet re-
suspend with 250 µL solution A which contains both (0.3 M sucrose and 0.01 M 
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sodium acetate pH=4.5) and vortex mixed until it completely re-suspended. 250 µL of 
solution B which contains (2% sodium dodecyle sulfate and 0.01 M sodium acetate 
pH=4.5) was added and then transfer to ribolyser tube then add 500 µL before leaving 
the solution to incubate at room temperature for 2 - 3 minutes. Cell were lysed by 
using Habaid Ribolyser (speed 6 for 20 to 40s) each time and the sample keep the on 
the ice for 1 min, it was then centrifuged for 5 minutes at 15000 rpm at 4 OC and 
aqueous phase was transferred to new tube 1.5 ml Eppendorf. 500 µL of phenol was 
added and incubated 4 min at 64 oC then direct frozen in dry ice ethanol for 10s and 
mixed with inverting the tube 4 – 6 times followed by centrifugation at 15,000 rpm 
for 5 minutes at 4 OC, transfer Aquose phase to new tube 1.5 ml Eppendorf. 500 µL 
of phenol- chloroform were added and mixed by vortex for 45s and centrifuged for 5 
min at 15,000 rpm at 4 oC. The nucleic acid was predicated with 60 µL 0.01 M sodium 
acetate pH=4.5 and 940 µL of 100 % ethanol and keep the tube in – 20 oC overnight 
then centrifugation at 15,000 rpm for 30 min at 4 OC thereafter discarding the 
supernatant and the pellet should be washed by 70 % ethanol.  To remove all ethanol, 
leave the tube in room temperature to dry for 10 – 15 min.  RNA was dissolved in of 
diethylpyrocarbonate (DEPC) treated water add 50 µL. The quantity and concentration 
of RNA was determined by spectrophotometrically using a NanoDrop ND-2000 
spectrophotometer (Thermo Scientific United Kingdom) by measuring the absorbance 
ratio between A260 and A280. In addition, the RNA was checked by electrophoresis on a 
1% (w/v) TAE agarose gel. 
2.2.1.8 Genomic DNA degradation 
 
The genomic DNA was removed from the total RNA extract by using RNase-free, 
DNase I (New-England Biolab), following the manufacturer’s instructions.  
2.2.1.9 Purification of RNA 
 
To removal of all traces of DNA, RNA was cleaned and concentrated according to the 
manufacturer’s instructions (Zymo Research). Finally RNA cleaned was dissolved in 
40 µl of diethylpyrocarbonate (DEPC) treated water. 
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2.2.1.10 First strand complementary DNA (cDNA) synthesis 
 
RNA was reverse transcribed to first strand complementary DNA (cDNA) using 
cDNA Superscript II RT. First-Strand Synthesis kit (Invitrogen, UK), according to the 
manufacturer’s instructions. Between 100 and 200 ng of total RNA was used as a 
template for cDNA synthesis. cDNA formed was mixed with 50 µl  of 
diethylpyrocarbonate (DEPC) treated water, control PCRs were similarly performed 
with RNA untreated by reverse transcriptase to confirm the absence of contaminating 
DNA in the RNA preparations cDNA, store it at -20ºC for future use. 
2.2.1.11 Reverse transcription- polymerase chain reaction (RT-PCR) 
 
RT-PCR was carried out using a cDNA template to investigate the expression genes 
form selected antibiotic biosynthesis gene clusters (methylenomycin, lantibiotic, poly 
unsaturated fatty acid) in Streptomyces coelicolor W81and M145. These set of genes 
typically include biosynthetic genes, resistance genes and pathway-specific 
transcriptional activators for methylenomycin (O'Rourke et al., 2009) and lantibiotic, 
poly unsaturated fatty acid. PCR was used to amplify the cDNA target sequence of 
gene using two designated primers (see previous method for PCR Table 12 and 13). 
Primer sequences are summarized in Table 5, 6 and 7. PCR product samples were 
analysed on 1% agarose gels (AGTC Bioproducts) prepared in 1x Tris- Acetate 
electrophoresis buffer (TAE). 
2.2.1.12 Streptomyces genomic DNA extraction 
 
Genomic DNA extraction from Streptomyces was done using FastDNA TM spin kit for 
soil (Thermo scientific) as outlined in the manufacturer`s protocol with some 
modification. 20 µL of the bacteria sample was added to Lysing Matrix E tube along 
with 978 µL sodium phosphate buffers and 122 µL MT buffer before overtaxing for 2 
minute. The sample was then centrifuged for 5 minutes at 4000 rpm at 4 OC and the 
supernatant was transferred to a clean 2.0 mL micro centrifuge tube and the pellet 
discarded. This was followed by adding 250 µL of protein precipitation solution (PPS) 
and mix by using inverting the tube 6 – 10 times (do not use vortex). Tube was then 
spun down at 15000 rpm for 5 minutes at 4 OC and the supernatant transferred to a 
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clean 15 mL tube. Add 1000 µL re-suspend binding matrix to this 15 mL tube. The 
tube should be inverted for 2 minutes that will help the binding of the DNA then place 
the tube in a rack for 2 – 3 minutes to allow setting of the silica matrix. Remove and 
discard 500 µL of supernatant. The re-suspended binding matrix was then transferred 
into a spin column with a filter (provided by the kit) and centrifuged for 60 seconds at 
15000 rpm at 4 oC and the flow through discarded. The remaining mixture was then 
added to the spin filter and centrifuge as before, then  washed with 500 µL SEWS-M, 
gently suspending the pellet using the force of the liquid from the pipette tip, then 
centrifuged for 15000 rpm for 60 second at 4 OC, discard the flow through, then 
centrifuged again for 15000 rpm for 2 minute at 4 OC to remove ethanol, discard the 
flow through then leave the filter spin column in safety cabinet for 5 - 10 minutes to 
dry all the ethanol , the plasmid was eluted in clean  micro tube by adding 50 - 55 µL 
of filtered sterile distilled water (was kept at 60 oC) then centrifugation at maximum 
speed 15000 rpm for 2 minute. NanoDrop ND-2000 spectrophotometer (Thermo 




Two different protocols were employed for transformation of E.coli with plasmid 
DNA cells. 
2.2.2.1 Preparation of chemically competent E. coli 
 
The E. coli strain TOP10 is widely used as a host cell for gene cloning. A sterile loop 
was used to streak E. coli TOP10 from frozen stock on the surface of a Luria Broth 
agar (LB agar) plate (without using antibiotic) and then the plate was incubated for 
around 17 - 19 hours at 37 oC. After incubation a single colony was transferred into 
10 mL of a Luria Broth (LB). The cells were grown for around 17 - 19 hours at 37 OC. 
The following day 1000mL of LB broth was inoculated with 10 mL of the overnight 
culture and cells were incubated for 2.5 to 3 hours at 37 °C or until the optical density 
at 600 nm (OD600) reached around 0.4 – 0.5. Thereafter, cells were harvested by 
centrifugation at 4000 rpm for 10 minutes and then the cell pellet was re-suspended in 
30 mL sterile ice - cold Tfbl buffer which was composed of 30 mM K-acetate, 50 mM 
MgCl2, 100 mM KCl, 10 mM CaCl2 and 15% glycerol, pH 7.4 and incubated on ice 
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for 30 minutes. The cell pellet was collected by centrifuge at 4000 rpm for 10 minute 
in 4 oC and after that the pellet re-suspended in 4 mL TfbII buffer, which was 
composed of 10 mM Na-MOPS, 75 mM CaCl2, 10 mM KCl and 15% glycerol, pH 
7.4, 50 µL of the competent cells were then aliquoted into micro-centrifuge tubes and 
transferred immediately to -80 OC or was kept on ice for immediate transformation 
(Hanahan, 1983). 
2.2.2.2 Transformation of chemically competent E. coli 
 
3 μl of the ligation product (pJH2, pJT1 and pVN3) were transferred into 50 μl of 
chemical competent E. coli TOP10 strain then mixed gently and incubated on ice for 
15 - 20 minutes after which the cells were heat shocked in water bath at 37 OC for 2 
minutes before being immediately transferred onto ice again where they were 
incubated for 5 minutes. 50 μL of this mixture was then transferred into falcon tube 
containing 500 μL of LB broth and incubated at 37 OC for 1 – 1.5 hours with shaking. 
After that two different volumes were plated on LB media has ampicillin (100 μg/mL) 
for example 10 µL on one and 460 µL on the other plate. These were then incubated 
for overnight at 37 OC. After this, a single colony was picked up using a sterile tip and 
used to inoculate 10 mL of LB broth medium containing 100 μg/mL of ampicillin 
before incubation overnight at 37 OC with shaking 200 RPM. The plasmid DNA was 
then isolated and purified by using Gene JET plasmid mini-prep (Thermos Scientific 
United Kingdom). The solution should be run on 1% agarose gel electrophoresis in 
order to check the size of the expected band. 
2.2.2.3 Preparation of electro-competent cells 
 
A sterile loop was used to streak E.coli (strain ET12567/ pUZ8002) from frozen stock 
on the surface of a Luria Broth agar (LB agar) plate used contain kanamycin 50 
(µg/mL) and chloramphenicol 35 µg/ml then the plate was incubated for an around 17 
- 19 hours at 37 oC. After incubation, a single colony was transferred into 10 mL of a 
Lysogeny Broth (LB) with the same selection antibiotics. The cells were grown for 
around 17 - 19 hours at 37 OC. The E.coli electro-competent cells were prepared by 
adding 100 µL of an overnight cell culture to 10 ml of LB and incubating until the 
culture reached an OD600 ≈ 0.4 - 0.5 nm. The culture was subjected to centrifugation 
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and then the supernatant was removed. The cell pellet was washed two times with 10 
mL of sterile ice-old 10% glycerol. Finally, the pellet was re-suspended in 70 μL of 
10% glycerol. It then was ready for the electroporation technique. 
2.2.2.4 Electroporation 
 
For electroporation, a 70 μL aliquot of electro-competent cells were mixed with 3 µL 
of plasmid DNA in an electro-cuvette. Cuvettes were pulsed once with a time constant 
of ~ 23 ms and the following settings: 2.5 kV (voltage), 2.5 μF (capacitance). After 
electroporation the mixture 1 ml of ice-cold LB was immediately added and the 
mixture incubated for 1 hour at 37°C with gentle shacking at 210 rpm. The bacterial 
cells were then grown on LB plates containing kanamycin 50 µg/mL, ampicillin 50 
µg/mL and chloramphenicol 35 µg/mL overnight at 37 oC. 
2.2.3 Assessment of the DNA fragments size. 
The purified DNA construct ligated into vector was digested (Thermo Scientific 
United Kingdom) as follows using supplier instructions with some modification using 
the following protocol: 
1. Linearized: 
Restriction enzyme HindIII  1µL 
DNA plasmid    1.5 µg 
10X buffer    5µL 
Sterile distilled water up to  50µL   
 
The reaction mixture was incubated either in water bath at 37 oC for 2 hours or 
overnight at 4 OC. After incubation period, this reaction solution was run on 1% 
agarose gel electrophoresis in order to check the size of the expected band. 
2. Excised: 
Restriction enzyme HindIII and PstI  1 µL 
DNA plasmid     1.5 µg 
10X buffer     5 µL 
Sterile distilled water up to   50 µL   
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The reaction mixture was incubated either in water bath at 37 oC for 2 hours or 
overnight at 4oC. After incubation period, this reaction solution was run on 1% agarose 
gel electrophoresis in order to check the size of the expected band. 
2.2.3.1 Screening the plasmid constructs by PCR 
 
PCR screening was used to amplify the DNA target sequence gene using two 
designated primers, the forward primer was designed using a restriction enzyme 
HindIII site and the reverse primer included the site for the restriction enzyme PstI 
(Table 6). 
The PCR master mix consisted of a taq DNA polymerase and buffer 10x, 25mM 
MgCl2 and dNTPs (Table 15). The reaction mixture went through 30 PCR cycles, to 
gain the amplification of DNA target sequence, in automated thermal cycler machine 
(Table 16). 
Table 15: Components and volumes were used for PCR reaction to amplify the DNA target. 
Component Volume 
Taq DNA buffer  (10 x) 5 μL 
dNTP mix. (10 mM) 1 μL 
forward primer mmyB forward-HindIII 1 μL 
revers primer mmyB reverse -PstI 1 μL 
Plasmid sample 0.5 μL 
Dimethyl sulfoxide (DMSO) 2.5 μL 
Taq DNA polymerase  1 μL 
MgCl2 (25 mM) 3 μL 
Distilled water up to 50 μL 35 μL 
Total 50 μL 
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Table 16: Cycling programme was used for PCR screen DNA gene ligated with pOSV556. 
Cycle Temperature  Time Total cycles 
Initial 
denaturation 
98 oC 2 Minute  
Denaturation 98  oC 45 second  
30 cycles Annealing 55 oC 45 second 
Extending 72 oC 1 minute 
Final extending 72 oC 15 minute  
Cooling down 4 oC ∞  
2.2.3.2 Assessment of the DNA by doing DNA sequencing 
 
Sequencing of specific DNA regions were done by GATC Biotech AC (European 
Custom Sequencing Center, Gottfried-Hagen-Strobe 20, 51105 Cologne, Germany). 
The total reaction volume was 10 μL composed of 5 μL of plasmid DNA, 2.5 μL of 
both primer and 2.5 μL sterile distilled water. 
2.2.4 Growth and storage the bacteria 
2.2.4.1 Growth E. coli bacteria 
 
E. coli cultures were grown at 37 °C using LB for overnight in solid or liquid cultures, 
shaking at 200 rpm in flasks for liquid cultures.  
2.2.4.2 E. coli glycerol stocks preparation 
 
E. coli cultures in broth LB media overnight at 37oC and diluted with equal volume 
with sterile 50% (v/v) glycerol to a final concentration of 25% before being stored at 
-80 °C. 
2.2.5 Growth of Streptomyces bacteria 
 
Streptomyces cultures were grown at 30 °C using SFM agar for 6-7 days in liquid or 
solid cultures, shaking at 200 rpm in flasks containing stainless steel spring for liquid 
cultures. 
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2.2.5.1 Streptomyces glycerol stocks preparation 
 
Streptomyces glycerol spore stocks were prepared (Shepherd et al., 2010) with some 
modification. After incubating at 30 °C for six days spores were grown on SFM plates 
with appropriate antibiotics. Around 3 mL sterile water was added to each plate. A 
sterile loop was used to free the spores and do suspension. The suspension was filtered 
through a sterile syringe with non-absorbent cotton wool to remove any agar that had 
been picked up and pelleted by centrifugation (3,500 rpm for 5 minutes). The 
supernatant was removed. The spore pellet was re-suspended in the residual liquid 
exactly 1 ml then add equal volume with sterile 50% (v/v) glycerol to a final 
concentration of 25% before being stored at -80 °C. 
2.2.5.2 Transfer of the plasmid with a gene cassette into Streptomyces 
 
The plasmid (pJH2, pJT1 and pVN3) were introduced by transformation into the non-
methylation E. coli ET12567/pUZ8002. The plasmid was then transferred to 
Streptomyces coelicolor by intergenic conjugation according to standard methods 
(Kieser, 2000) with some modification as described below.  
After incubation a single colony which carried a plasmid was transferred into 10 mL 
of a Luria Broth agar (LB agar) which contained of ampicillin (100 µg/mL), 
kanamycin (50 µg/mL) and chloramphenicol (23 µg/mL). The cells were grown for 
17 - 19 hours at 37 OC. The culture was subjected to centrifugation and then the 
supernatant was removed. The cell pellet was washed two times with 10 mL of sterile 
LB media to remove antibiotics that might inhibit Streptomyces then re-suspend in 500 
µL of LB.  Add 10 μL of Streptomyces coelicolor spores to 500 mL 2XYT, then heat 
shock at 50°C for 10 min, then allowed cooling. Mix 500µL of E. coli 
ET12567/pUZ8002 cell suspension and 500 µL heat-shocked spores and spin briefly 
at 5000 rpm for 30 second, re-suspension the pellet in the residual liquid. Serial 
dilution should be done from 10-1 to 10-4. Of each dilution 100 μL was used to 
inoculate plates on SFM which containing of 10 mM MgCl2 (to help the colonies 
sporulation) these were then incubated for 18- 20 hours at 30 OC. The next day, overlay 
the plate with 1 mL sterile distilled water containing 20 µL naldixic acid (from 25 
mg/mL stock) to kill E. coli, 25 µL of 100 mg/mL stock ampicillin and 25 µL of 50 
mg/mL stock hygromycin to select the Streptomyces exconjugants. A spreader was 
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not used for this, instead the plate was tilted until evenly covered with the antibiotic 
solution, then wait until the plate have dried and then keep it again in incubation at 30 
oC for 6 days to allow growth of the exconjugants. 
2.2.6 Analytical chemistry 
2.2.6.1 Organic extraction  
 
Two different protocols were employed for organic solid-liquid and liquid-liquid 
extraction. 
2.2.6.1.1 Organic extraction Liquid-Liquid  
 
Organic Liquid-Liquid extraction means that two liquids are used in the extraction 
procedure using a separator funnel. The culture was centrifuged around 4,000 rpm for 
15 - 20 minutes to remove the bacteria. The liquids must be immiscible: this means 
that they will form two layers when added together. First of all, using pJH2 integrated 
into the S. coelicolor W81 chromosome, 10 µL were transferred into 50 µL of SMM 
broth then add equal volume of Ethyl acetate the sample should be acidified to pH 3 
with 37% Hcl. The solution should be mixed then a separator funnel used to separate 
the two liquid layers separate. The organic solvent and water are not miscible with 
each other. Add the liquid to separator funnel. Shake the funnel vigorously for a few 
seconds. Put the funnel back into the ring until the layers are clearly separated. While 
waiting, remove the stopper and place a beaker or flask under the separator funnel. 
Carefully open the stopcock and allow the lower layer to drain into the flask. The 
upper layer should separate from the funnel in clean flask, this was labeled and 
magnesium sulfate added to remove all water before clean filter paper was used to 
remove all magnesium sulfate. The remaining solvent should be removed by using a 
rotary evaporator. Add 150 µL DMSO to dissolve the entire component in the flask. 
The solution was eluted into clean micro tube which is ready to test in antibiotic assay 
or re-dissolved with HPLC grade methanol and water re-dissolved in 500 μL 50:50 to 
run in LCMS by using the Agilent 1200 HPLC coupled to the Bruker High Capacity 
Trap (HCT) Ultra mass spectrometer. 
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2.2.6.1.2 Organic extraction Liquid-Solid 
 
Organic extraction liquid-solid used agar media, add 30 mL Ethyl acetate. It should be 
acidified to pH 3 with 37% Hcl, same technique used in Liquid-Liquid but without 
using magnesium sulfate. 
2.2.6.1.3 Liquid chromatography – mass spectrometry (LC - MS) 
 
The LC-MS analysis of any crude extract results to compare of two samples. Organic 
extracts were filtered on a spin column around 5000 rpm for 5 minutes then injected 
20 μL through Agilent ZORBAX Eclipse Plus column C18, 46 x 150 mm, particle 
size 5 μm connected to Agilent 1200 HPLC coupled to the Bruker High Capacity Trap 
(HCT) Ultra mass spectrometer, operating in positive ion mode, The solvent and linear 
gradient profile with a flow rate of 1 mL/minute were used in LC-MS analysis see 
Table 17.  






+ 0.1% formic acid 
(%) 
Methanol 
+ 0.1% formic acid 
(%) 
0 95 5 
5 95 5 
30 0 100 
35 0 100 
40 95 5 
55 95 5 
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2.2.7 Antibiotic assay 
 
All media were prepared according to the manufacturer’s instructions, and sterilised 
by autoclaving at 121°C for 15 min. The antibiotic sensitivity assay shows the ability 
of drug in inhibiting the growth of microorganisms. Bacillus subtilis, Staphylococcus 
aureus and E. coli stocks were plated on LB agar and incubated for around   17 - 19 
hours at 37 oC after incubation a single colony was transferred into 10 mL of a Luria 
Broth (LB). The cells were grown an around 17 - 19 hours at 37 OC in a shaking 
incubator at 200 rpm. The bacteria cells were then prepared for the antibiotic assay by 
adding 200 µl of this overnight cell culture to 10 ml of LB and incubating until the 
culture reached an OD600 ≈ 0.4 - 0.5 nm. 50 µL of this bacteria strain culture then 
added to 1 mL LB broth and used to overlay LB agar plate not containing antibiotic, 
this was done without using spreader and tilting the plate instead and wait until all the 
solution has evaporated. The sterile filter paper to 6 mm discs were then placed onto 
of the bacteria plated before adding 21 µL either direct from culture or from organic 
extraction liquid-liquid as described previous then incubated overlay LB agar around 
18 - 20 hours at 37 OC. 
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3 Chapter 3: Overexpression of the transcriptional 
activator gene mmyB in S. coelicolor  
 
The MmyB protein is found in Streptomyces coelicolor A3(2). It is a proposed to be a 
transcriptional activator for the methylenomycin biosynthetic gene cluster. The 
methylenomycin biosynthetic gene cluster is tightly regulated at the transcriptional 
level, and is usually not produced and if it is produced, then it is produced in a very 
small quantity in laboratory growth conditions (O'Rourke et al., 2009). 
Overexpression of transcriptional activators under the control of ermEp* (ermEp* is 
promoter which originated from erythromycin resistant gene) is expected to unlock 
the production of compounds from neighbouring cryptic biosynthetic gene clusters. 
To investigate this, an experiment was performed determine if overexpression of this 
activator will switched on the methylenomycin biosynthetic genes cluster and express 
other mmy gene to produce the methylenomycin antibiotics illustrated in Figure 4. To 
this end, it is very important to clone the mmyB gene in the pOSV556 vector (which 
has the ermEp* promotor) and then introduce it into S. coelicolor W81. 
In order to do this, PCR was used to amplify specific the mmyB gene. Two primers 
were designed (mmyB forward and reverse) (Primers number T01 in Table 4). PCR 
products were analysed by electrophoresis on a 1% agarose gel in order to verify the 
size of the construct which yields a band at the expected 994 bps (Figure 10). A 
NanoDrop ND-1000 spectrophotometer was used to measure the concentration of the 
mmyB construct (273.4 ng/ μl). 
The pOSV556 plasmid was isolated from Escherichia coli DH5α and purified using a 
Gene JET plasmid mini-prep kit yielding purified pOSV556 plasmid. A NanoDrop 
ND-1000 spectrophotometer was used to measure the concentration (963 ng/µl). The 
plasmid produced a band at the expected 9009 bps on a 1% agarose gel. The plasmid 
contains ampicillin and hygromycin resistant genes which were used as selection 
markers for successful transformations when these vectors were introduced into S. 
coelicolor strains using intergenic conjugation.  
This process was facilitated with various genes included in the vector such as: 
1. attP – which allows integration into S. coelicolor, 
Chapter 3: Overexpression of the transcriptional activator gene mmyB in S. coelicolor 
46 
 
2. OriT – Origin of transfer (allows conjugation and recognition by Streptomyces 
and helps with transfer of genes), 
3. Ter – transcriptional terminator (where the mRNA finishes) (Figures 11A 
&B). 
The plasmid created by this ligation was termed pJH2 (containing mmyB under the 
control of ermEp*). Plasmid pJH2 was grown in E.coli Top10 and purified using 
the mini-prep procedure; the agarose gel run following the mini-prep of the 
construct is shown in Figure 12. This construct was then ready to transform into 
non-methylation E. coli ET12567/pUZ8002 host cell (by electroporation) to 
introduce into S. coelicolor W81 because the S. coelicolor W81 contains a methyl-









Figure 10: PCR was used to amplify mmyB. This reaction solution was run on 1% agarose gel in order 
to verify the size of the expected band, at around 994 bps (Lane 1) compared to a FastRuler middle 

























Figure 11: A) Purification of plasmid pOSV556 to verify the size of the expected band 9009 bp (Track 
1 and 2) by comparing it to a FastRuler high range DNA ladder (Track L). B) Schematic map diagram 











Figure 12: Schematic map for the mmyB ligated into pOSV556 which has been named pJh2 and is 9981 
bps in size.  
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Screen of the vector for correct insert 
The pOSV556 vector containing the cloned mmyB gene (pJh2) was linearized with 
HindIII giving a band of 9981 bps. The cloned mmyB gene was recovered from the 
plasmid using restriction enzymes HindIII and PstI giving the expected band size of 







Figure 13: Assessment of the pJH2 fragment size. The purified mmyB construct was ligated into 
pOSV556 vector and was digested using the restriction enzyme HindIII and PstI. This was then run on 
a 1% agarose gel in order to check the size of the expected bands. FastRuler high range DNA ladder 
(Track L), the size of the linearized plasmid was 9981 bps (Track 3), the size of the excised the mmyB 
insert 994 bps and vector is 9009 bps (Track 2). The pOSV556 band 9009 bps as positive control for 
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 Screen of the vector via PCR amplification 
 
PCR screening was used to amplify the mmyB target sequence of gene using two 
primers (T01 in Table 4). PCR products were run on a 1% agarose gel in order to 
verify the size of the expected band which was 994 bps (Figure 14). At this stage, the 
mmyB construct after cloning was sent for sequencing analysis to verify that no 
mutations had taken place during the cloning steps and this was confirmed in the 









Figure 14: Assessment of the mmyB by doing PCR amplification used two primers. This was then run 
on a 1% agarose gel in order to check the size of the expected band. FastRuler high range DNA ladder 
(Track L). The mmyB insert around 994 bps and vector is 9009 bps (Track 1). The pOSV556 band 
around 9009 bps as positive control (Track 2). Positive control was for the mmyB gene (Track 3). 
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 Assessment of pJh2 in S. coelicolor W81 using genomic 
DNA extraction and PCR screening  
 
To introduce the pJh2 plasmid into S. coelicolor W81, non-methylating E. coli 
ET12567/pUZ8002 host cells (by electroporation) were required to transfer the 
plasmid using intergenic conjugation, this is because S. coelicolor W81. The construct 
was successfully introduced through conjugation in S. coelicolor W81. After genomic 
DNA extraction of pJh2, which was integrated into S. coelicolor W81, a concentration 
of 317 ng/µl for the purified plasmid was obtained. PCR screening was used to amplify 
the DNA target sequence of the gene using two designed primers. The PCR products 
were run on 1% agarose gel and observed a single band around the expected size of 
994 bps (Figure 15).  
Using intergenic conjugation, we were hence able to successfully integrate the mmyB 









Figure 15: Assessment of the genomic mmyB by using PCR amplification for pJh2 integrated in S. 
coelicolor W81 after genomic DNA extraction technique (Track 1). FastRuler High range DNA ladder 
(Track L). Positive control used mmyB ligated pOSV556 (Track 2). S. coelicolor W81 only was used 
as negative control (Track 3). 
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 Transcription analysis of the methylenomycin 
biosynthetic genes through RT-PCR 
 
To find the expression-specific pathway after overproduction of pJH2 integrated in S. 
coelicolor, reverse transcription-PCR was performed on the extracted total RNA from 
pJH2 integrated into S. coelicolor W81 and wild type S. coelicolor W81.  
Total RNA was extracted from S. coelicolor W81 strain in which pJh2 was integrated 
into. Three expected bands representing intact ribosomal RNA were observed with the 
total RNA concentration of 779 ng/ µl. RNA products were run on 1% agarose gel (in 
order to verify the size of the expected bands 5s, 16s and 23s) (Figure 16). 
The RNA was converted into single stranded complementary DNA (cDNA) by using 
cDNA Superscript II RT. cDNA products were analysed by electrophoresis on 1% 
agarose gel as shown in Figure 17. As a control, a sample with no reverse transcriptase 
used to ensure that the results observed are that of the amplification of cDNA and not 
DNA contamination. 
The cDNA synthesised were used as a template in thermal cycler reactions to 
determine if mmyB gene was transcribed. PCR products were analysed by 









Figure 16: Total RNA was extracted from S. coelicolor W81/pJH2 grown in MMS broth.  This reaction 
solution was run on 1% agarose gel and ribosomal RNA were clearly observed in three bands (Track 



















Figure 17: mRNA isolated from pJH2 integrated in S. coelicolor W81 was reverse transcribed to 
complementary DNA (cDNA) using cDNA Superscript II RT (Track 1). The negative control was 
performed using without reverse transcriptase to cDNA to confirm no DNA contamination (Track 2). 
FastRuler middle range DNA ladder (Track L). 









Figure 18: A) pJH2 integrated in S. coelicolor W81 expression mmyB using RT-PCR (Track 1). The 
negative control was performed using S. coelicolor W81 without pJH2 (Track 2) and the positive 
control is construct used to amplify the DNA target sequence of gene using same two designated primers 
by using template genomic DNA extracted from S. coelicolor A3 (2) (Track 3). FastRuler middle range 
DNA ladder (Track L). B) The second negative control was performed using minus RT-PCR using 
same two designated primers (Track 3). Track 4 shows control primers designed to amplify the hrdB 
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3.3.1 Transcription analysis by RT-PCR for mmyO, mmyJ, mmyD, 
mmyF, mmyG, mmyQ and mmyB 
 
RT-PCR was used to test expression of selected gene from methylenomycin 
biosynthetic gene cluster. For this purpose sixteen different primer-pairs (Table 7) 
representing eight members of mmy genes (mmyO, J, D, E, F, G, Q, and B) were 






















Figure 19: Analysis of the expression of a selection mmy genes mmyO, J, D,E,F,G,and Q in S. 
coelicolor W81 pJH2 using RT-PCR (Track 1). The negative control was performed using S. coelicolor 
W81 (Track 2) and also negative control was performed using minus RT-PCR using same two 
designated primers (Track 3). In Track 4 using as a control primers designed to amplify the hrdB gene 
considered to be constitutively expressed. FastRuler middle range DNA ladder (Track L). 
100 
100 
L    1    2   3      4     L      1     2    3    4     L      1    2  3  4  
mmyO mmyJ mmyD 
L   1  2  3   4   L   1  2   3   4   L   1  2   3    4  L    1   2 3 4 
mmyF mmyG mmyQ mmyB 







Chapter 3: Overexpression of the transcriptional activator gene mmyB in S. coelicolor 
54 
 
 Methylenomycin production by overexpression of 
mmyB 
3.4.1 S. coelicolor W81 with and without pJH2 growth conditions   
 
In order to confirm that the construct has been incorporated in S. coelicolor, the 
pOSV556 vector containing the cloned mmyB gene (pJh2) was transferred to 
Streptomyces coelicolor by intergenic conjugation then kept in incubation at 30 oC for 
6 days to allow growth of the exconjugants in SFM agar.  It was observed that the 
plate with integrated overproduction with pJH2 shows growth and produced dark blue 
pigments (plate 1 Figure 29). However the wild type shows red pigment. From this it 
can be concluded that after integration of the pJh2 plasmid, it was able to switch on 
the silent pathway and produced methylenomycins antibiotics. However, in the wild 











Figure 20: Culture plates of streptomyces coelicolor W81 after growth for 6 days at 30 oC which contain 
the plasmid pJh2 that was integrated into S. coelicolor W81 (plate 1), S. coelicolor W81 growth without 
integrated pJH2 as wild type (plate 2) and using SFM media without inoculation of any bacteria as 
negative control (plate 3).   
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3.4.2  Antibiotic assay  
 
In order to confirm that after integration of the pJh2 plasmid, it was able to switch on 
the silent pathway and produced methylenomycins antibiotics. All the eight mmy 
genes (mmyB, O, J, D, F, G, Q and mmyE) were expressed when the mmyB was 
integrated in S. coelicolor W81. Antimicrobial activity of S. coelicolor W81/ pJh2 was 
tested using antibiotic sensitivity assay. The antibiotic sensitivity assay shows the 
ability of a drug in inhibition zone for the growth of the bacteria such as Bacillus 
subtilis, E. coli and S. aureus around the S. coelicolor W81/ pJh2 (Figure 21). The 
positive control was Apramycin Track 2, the antibiotic drug of the plasmid pJh2 was 
integrated into S. coelicolor W81 and metabolites were tested after organic extraction 
showing zone of inhibition (Track 1). 
Hence it can be deduced that methylenomycin antibiotic are produced.  
  






















Figure 21: Antibiotic assay used Bacillus subtilis on LB agar pH 5. The plasmid pJH2 was integrated 
into S. coelicolor W81 and metabolites were tested after organic extraction showing zone of inhibition 
(Track 1). Apramycin used as positive control (Track 2), S. coelicolor W81 only without the pJH2 was 
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Lantibotics act as antibiotics and are  produced by a different Gram-positive bacteria 
(Jung et al., 1991) and can kill other Gram-positive bacteria by inhibiting cell wall 
synthesis (VÉRIEST et al., 1999). Lantibiotics are ribosomally synthesised peptides, 
in which some amino acids are post-transitionally modified to non-natural amino acids 
(Sahl et al., 1995). Some examples of the non-natural amino acid that are created in 
lantibiotics are didehydroalanine, lanthionine, didehydrobutyrine and β-
methyllanthionine (Asaduzzaman et al., 2009). Some of the well-known members of 













Figure 22: The various commonly found lantibiotics include nisin A, The various commonly found 
lantibiotics include nisin A, Epidermin, Lacticin and Mersacidin. The encircled letters represent the 
amino acid (single letter code) (-S-) represents the thioether bound: A=Alanine, D=Aspartic acid, 
F=Phenylalanine, G=Glycine, H= Histidine, I= Isoleucine, K=Lysine, N= Asparagine, M= Methionine, 
P= Proline, S=Serine, V=Valine and Y=Tyrosine this picture taken from (McAuliffe et al., 2001). 
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The lantibiotic is created by the dehydration of certain serine (Ser) and threonine (Thr) 
residues with the addition of intramolecular of Cys thiols to the resulting in an 
unsaturated amino acids with the polypeptide chain (Figure 23) (McAuliffe et al., 
2001). 
Lantibiotics are considered as a member of bacteriocins that are classified according 
to their extent of post-translational modification. The lantibiotics can be categorised 
as extensively modified Class I bacteriocins. Bacteriocins for which disulphide bonds 














Figure 23: Lantibiotics synthesis, the picture taken from (McAuliffe et al., 2001).  
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Another classification of lantibiotics divides them into type A and type B based on 
their structural and functional features Table 18 (Jung et al., 1991). 
Table 18: Different type of lantibiotics (Jung et al., 1991). 
Lantibiotics 
tybes 
Structure  Length  Functions An example  
Type A Elongated Cationic 
peptides up 









Type B Globular Cationic 
peptides up 









4.1.1 Mechanism of action 
 
Lantibiotics show high specificity for some components of the bacterial cell 
membrane especially of Gram-positive bacteria. Small quantities of lantibiotics type 
A can kill Gram-positive bacteria rapidly because they can form pores in the cell wall. 
However, type B lantibiotics can inhibit the cell wall peptidoglycan biosynthesis 
(Brötz and Sahl, 2000). 
Lantibiotics contain the characteristic polycyclic thioether amino acids lanthionine or 
methyllanthionine, in addition to the unsaturated amino acids dehydroalanine and 2-
aminoisobutyric acid. Lanthionine is composed of two alanine residues that are cross-
linked on their β-carbon atoms by a thioether (monosulfide) linkage. Nisin and 
epidermin are well-studied lantibiotics that bind to lipid II, and disrupt cell wall 
production. On the other hand, the duramycin family of lantibiotics binds 
phosphoethanolamine in the membranes of its target cells leading to the disruption 
essential physiological functions. Interestingly, some lanthionine containing peptides 
have been discovered that do not have any antibiotic activity (Goto et al., 2010). Some 
lantibiotic produced from different show in Table 19. 
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Table 19: Lantibiotic produced from different strains of Gram-positive bacteria, the table taken from 
(McAuliffe et al., 2001).  
Lantibiotics Producing Strain  
Nisin A Lactococcus lactis NIZOR5, 6F3, NCFB894, 
ATCC11454 
Nisin Z Lactococcus lactis N8, NIZO22186 
Subtilin Bacillus subtilis ATCC6633 
Epidermin Staphylococcus epidermidis Tu3298 
Gallidermin Staphylococcus gallinarum Tu3928 
Mutacin B-Ny266 Streptococcus mutans 
Mutacin 1140 Streptococcus mutans JH1000 
Pep5 Staphylococcus epidermidis 5 
Epicidin 280 Staphylococcus epidermidis BN280 
Epilancin K7 Staphylococcus epidermidis K7 
Lacticin 481 Lactococcus lactis CNRZ481, ADRIA85LO30 
Cytolysin Enterococcus faecalis DS16 
Lacticin 3147 Lactococcus lactis DPC3147 
Staphylococcin C55 Staphylococcus aureus C55 
Salvaricin A Streptococcus salvarius 20P3 
Lactocin S Lactobacillus sake L45 
Streptococcin A-FF2 Streptococcus pyogenes FF22 
Sublancin 168 Bacillus subtilis 168 
Carnocin U149 Chryseobacterium piscicola 
Variacin 8 Micrococcus varians MCV8 
Cypemycin Streptomyces ssp 
Cinnamycin Streptomyces cinnamoneus 
Duramycin B Streptoverticillium ssp 
Duramycin C Streptomyces griseoluteus 
Ancovenin Streptomyces ssp 
Mersacidin Bacillus subtilis HIL Y-85, 54728 
Actagardine Actinoplanes 
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 Bioinformatics analysis for lantibiotic gene clusters 
regulated by sco6926 
Discovery of new natural products can be achieved via the genome mining approach; 
the genome sequence of a microorganism of interest can be obtained and analysed 
using bioinformatics tools to identify potential cryptic biosynthetic gene clusters 
(BGC’s). S. coelicolor has 16 proteins highly similar to MmyB shown in (Table 1) 
each of them responsible for controlling different pathways (Xu et al., 2012), 
SCO6926 may be involved in promoting biosynthesis of lantibiotic. Bioinformatics 
helps to identify the lantibiotics biosynthesis secondary metabolite gene clusters in S. 
coelicolor. Tools to do this include antiSMASH 
(http://antismash.secondarymetabolites.org/) and a lantibiotic biosynthetic gene 
cluster in S. coelicolor was successfully identified using AntiSMASH (Figure 24 A 
& B) and (Figure 25).  
In addition, it is useful for novel natural products discovery and bioinformatics tools 
such as the National Centre for Biotechnology Information (NCBI) BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and useful to identify proposed function and 
proteins for all the genes of lantibiotic metabolite gene clusters in Table 20. The 
SCO6926 protein is found in Streptomyces coelicolor A3(2). It is a proposed pathway 
specific transcriptional activator for the lantibiotic biosynthetic gene cluster. 
 
 
















Figure 25: Proposed the lantibiotic genes cluster contain 24 genes 




Table 20: Proposed function of the biosynthetic genes from the sco6926 cluster. 
Genes Protein 
(number of aa) 
GenBank 
Homologue (% identity 

































































































sco6931 WP_011031313.1   
59 aa 
FxLD family 


























































































































633 aa   





Glucoamylase   
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 Overexpression sco6926 gene from S. coelicolor M145 
The SCO6926 protein is found in Streptomyces coelicolor A3(2). It is proposed to be 
a transcriptional activator for the lantibiotic biosynthetic gene cluster. The lantibiotic 
biosynthetic gene cluster is tightly regulated at the transcriptional level, and is usually 
not produced or produced in a very small quantity in laboratory growth conditions. 
Overexpression of transcriptional activators under the control of ermEp* is expected 
to unlock the production of compounds from expression of the neighbouring cryptic 
biosynthetic gene clusters. To investigate this, an experiment was performed 
determine if overexpression of this activator switched on the lantibioitc biosynthetic 
genes cluster will expressed the own genes to produce the lantibiotic antibiotics. To 
this end, cloned sco6926 in to the pOSV556 vector under the control of the ermEp* 
promotor and then introduced it into S. coelicolor M145. 
 
PCR was used to amplify specific sco6926 sequences. Two primers were designed 
(forward and reverse) (T03 in Table 4). High-Fidelity PCR amplification was used to 
amplify a target region of sco6926 for cloning purposes using PCR reaction. PCR 
products were run on 1% agarose gel in order to verify the size of the expected band 
which was 825 bps (Figure 26 A). A NanoDrop ND-1000 spectrophotometer was 
used to measure the concentration of the sco6962 (304 ng/ μl). 
 Digestion and ligation of plasmid pOSV556 followed by insertion of sco6926 were 
performed as part of cloning and plasmid analysis. The plasmid created by this ligation 
is known as pJT1 (containing sco6926 under the control of ermEp*). Plasmid sco6926 
was amplified in E.coli Top10 strain and purified using the mini-prep procedure; the 
agarose gel run following the mini-prep of the construct is shown in Figure 26 B. This 
construct was then ready to transform into non-methylating E. coli ET12567/pUZ8002 
host cell (by electroporation) to introduce into S. coelicolor M145. 
  















Figure 26: A)  PCR was used to amplify sco6926. This reaction solution was run on 1% agarose gel in 
order to verify the size of the expected band, at around 825 bps (Track 1) compared to a FastRuler 
middle range DNA ladder (Track L). B) Schematic map for the sco6926 ligated into pOSV556which 
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4.3.1 Screen of the vector via PCR amplification  
 
PCR screening was used to amplify the sco6926 target sequence of gene using two 
primers (T03 in Table 4). PCR products were run on 1% agarose gel in order to verify 
the size of the expected band which was 825 bps (Figure 27). At this stage, the DNA 
construct after cloning was sent for sequencing analysis to verify that no mutations 














Figure 27: Assessment of the sco6926 by doing PCR amplification used two primers. This was then 
run on a 1% agarose gel in order to check the size of the expected band. FastRuler high range DNA 
ladder (Track L). The sco6926 insert around 825 bps and vector is 9009 bps (Track 1). The pOSV556 
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4.3.2 Assessment of the pJT1 in S. coelicolor M145 using genomic 
DNA extraction and PCR screening  
 
To introduce the pJT1 plasmid into S. coelicolor M145, non-methylating E. coli 
ET12567/pUZ8002 host cells (by electroporation) were required to transfer the 
plasmid using intergenic conjugation, this is because S. coelicolor M145 contains a 
methyl-sensing restriction system. The construct was successfully introduced through 
conjugation in S. coelicolor N145. After genomic DNA extraction of pJT1, which was 
integrated into S. coelicolor M145, a concentration of 201 ng/µl for the purified 
plasmid was obtained. PCR screening was used to amplify the DNA target sequence 
of the gene using two designed primers. The PCR products were run on 1% agarose 
gel and observed a single band around the expected size of 825 bps (Figure 28). Once 
screened, this plasmid was transferred into S. coelicolor M145 via conjugation.  
Using intergenic conjugation, we were hence able to successfully integrate the 









Figure 28: Assessment of the genomic sco6926 by using PCR screen for pJT1 integrated in S. 
coelicolor M145 after genomic DNA extraction technique (Track 1). ). S. coelicolor M145 only was 
used as negative control (Track 2). Positive control used construct of sco6269 ligated pOSV556 (Track 
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 Transcription analysis of the lantibiotic biosynthetic 
gene through RT-PCR 
 
To find the expression-specific pathway after overproduction of pJT1 integrated in S. 
coelicolor, reverse transcription-PCR was performed on the extracted total RNA from 
pJT1 integrated into S. coelicolor M145 and wild type S. coelicolor M145.  
Total RNA was extracted from S. coelicolor M145 strain in which pJT1 was integrated 
into. Three expected bands representing intact ribosomal RNA were observed with the 
total RNA concentration of 187 ng/ µl. RNA products were run on 1% agarose gel (in 
order to verify the size of the expected bands 5s, 16s and 23s) (Figure 29). 
The RNA was converted into single stranded complementary DNA (cDNA) by using 
cDNA Superscript II RT. cDNA products were analysed by electrophoresis on 1% 
agarose gel as shown in Figure 30. As a control, a sample with no reverse transcriptase 










Figure 29: Total RNA was extracted from Streptomyces coelicolor M145 / pJT1 grow in MMS broth.  
This reaction solution was run on 1% agarose gel and ribosomal RNA were clearly observed (Track 






















Figure 30: mRNA isolated from pJT1 integrated in S. coelicolor M145 was reverse transcribed to 
complementary DNA (cDNA) using cDNA Superscript II RT (Track 1). The negative control was 
performed using minus reverse transcriptase to cDNA to confirm no DNA contamination (Track 2). 
 
4.4.1 Transcription analysis by RT-PCR for Sco6926, sco6927, 
sco6932 and sco6933 
 
RT-PCR was used as test expression of selected gene from lantibiotic biosynthetic 
gene cluster. For this purpose eight different primer-pairs (Table 7) representing four 
members of sco genes for examples sco6926, sco6927, sco6932 and sco6933 were 
designed and their RT-PCR products were run on an agarose gel 1% and are shown in 
(Figure 31). Additional experimental show in the appendix. 
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Figure 31: Analysis of the expression of a selection sco genes sco6926, 27, 32 and sco6933 in S. 
coelicolor M145/pJT1 using RT-PCR (Track 1). The negative control was performed using S. 
coelicolor M145 (Track 2) and also negative control was performed using minus RT-PCR using same 
two designated primers (Track 1). In Track 4 using as a control primers designed to amplify the hrdB 
gene considered to be constitutively expressed. 
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 Bacterial growth conditions and antibiotic assay 
 
4.5.1 S. coelicolor M145 with and without pJT1 growth conditions   
 
In order to confirm that the construct has been incorporated in S. coelicolor, the 
pOSV556 vector containing the cloned sco6926 gene (pJT1) was transferred to 
Streptomyces coelicolor M145 by intergenic conjugation according to standard 
methods by (Kieser, 2000), then keep it in incubation at 30 oC for 6 days to allow 
growth of the exconjugants in SFM agar (Figure 32). It was observed that the plate 
with integrated overproduction with pJT1 shows growth and produced bale red 
pigments (plate 1 Figure 42). However the wild type shows white pigment. From this 
it can be concluded that after integration of the pJT1 plasmid, it was proposed to switch 
on the silent pathway and produced lantibiotics antibiotics. However, in the wild type, 













Figure 32: culture plates S. coelicolor M145 after growth 6 days at 30 oC which contain the plasmid 
pJT1 was integrated into S. coelicolor M145 (plate 2), S. coelicolor M145 growth without integrated 
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4.5.2 Antibiotic assay 
 
In order to confirm that after integration of the pJh2 plasmid, it was able to switch on 
the silent pathway and produced methylenomycins antibiotics. All the four sco6926 
genes (sco6926, sco6927, sco6932, sco6933) were expressed when the sco6926 was 
integrated in S. coelicolor M145. Antimicrobial activity of S. coelicolor M145/ pJT1 
was test using antibiotic sensitivity assay. The antibiotic sensitivity assay shows the 
ability of drug in inhibition zone for the growth of the bacteria such as B. subtilis S. 
aureus but not active around the E. coli around the S. coelicolor M145/pJT1 (Figure 
33).  
  























Figure 33: Antibiotic assay used Bacillus subtilis, S. aureus and E. coli on LB agar pH 5. The plasmid 
PJT1 was integrated into S. coelicolor M145 and metabolites were tested and showing zone inhibition 
aureus but not active around the E. coli (Track 1). Apramycin used as positive control (Trach 2), S. 
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M145 pJt1 dO-methylt_BA3_01_4972.d: EIC (1459.21; 1460.55)±0.2 +All MS M145 pJT1_BA2_01_4971.d: EIC (1459.21; 1460.55)±0.2 +All MS
M145_BA1_01_4970.d: EIC (1459.21; 1460.55)±0.2 +All MS
1459.21
1460.55
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 Identification of predicted lantibiotic compounds in S. 
coelicolor M145 heterologous hosts 
In order to identify the predicted lantibiotics LC-MS of the SMM medium in which 
the cells are grown is performed. This is because any novel lantibiotics are synthesized 
by the cell after the incorporation of the new construct will be directed to the 
extracellular environment. Metabolites between the S. coelicolor with pJT1 
homologous host strains and S. coelicolor M145 wild type were compared by LC-MS 
and two new compounds were identified. The m/z= 1459.21 and 1474.93 were only 
present in S. coelicolor strains containing pJT1 and were absent in S. coelicolor M145 
control (Figure 34 A & B). Hence, we are able to identify two novel compounds which 











Figure 34: A) LC-MS trace of the predicted novel lantibiotic compound. Extracted ion chromatograms 
m/z = 1459.21. B) Extracted ion chromatograms m/z = 1474.93 which is not present when LC-MS of 
wild type is performed. 
  








M145 pJt1 dO-methylt_BA3_01_4972.d: EIC 1474.93±0.2 +All MS M145 pJT1_BA2_01_4971.d: EIC 1474.93±0.2 +All MS
M145_BA1_01_4970.d: EIC 1474.93±0.2 +All MS
1474.93
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5 Chapter 5: Polyunsaturated fatty acid gene 
clusters regulated by sco0110 
 
 Polyunsaturated fatty acid gene 
Lipids are fatty acid normally obtained from nutritional sources from foods. Fatty 
acids are carboxylic acids containing different lengths of carbon atoms that form a 
hydrocarbon chain. This chain is completed by carboxyl and methyl group. It is soluble 
in organic non-polar solvents. It can be classified like chains without double bonds 
between two adjoining carbon atoms are known as saturated fatty acids. 
Monounsaturated fatty acids have a single double bond, whereas polyunsaturated fatty 
acids two or more double bonds. the number of double bonds and the position of the 
initial double bond in the chain from the methyl functional group at the end of the 
chain, which is referred to as the ‘n’ or ‘ω’ carbon (Russell and Nichols, 1999, Yates 
et al., 2014). Polyunsaturated fatty acids (PUFAs) are important biomolecules in 
maintaining the health of living organisms. Therefore, they are known as essential 
fatty acids. However, animals cannot produce PUFAs because they lack some of the 
enzymes required for their biosynthesis. As a result, there is an increased interest in 
PUFA production in microorganisms (Elrazak et al., 2013).  
PUFAs can be referred to according to their organic structure. For example, 
arachidonic acid (ARA), which is presented as 20:4n−6, where 20 stands for the total 
number of carbon atoms, 4 indicates the number of double bonds and 6 shows that the 
position of the first double bond is on the 6th carbon from the terminal methyl (Abedi 
and Sahari, 2014, Yates et al., 2014). It is possible to distinguish between various 
families of PUFAs using this naming system. Also, some common examples of 
PUFAs found in microorganisms include docosahexaenoic acid (DHA) is presented 
as 22:6n−3, where 22 stands for the total number of carbon atoms, 6 indicates the 
number of double bonds, and 3 shows that the position of the first double bond is on 
the 3rd carbon from the methyl group (Abedi & Sahari 2014). For eicosapentaenoic 
acid (EPA), the structure is indicated as 20:5n−3. For decosapentaenoic acid (DPA), 
the structure is C22:5ω6, and for arachidonic acid (ARA), it is 20:4ω6 (Figure 35 A) 
(Hayashi et al., 2016). For dihomo-γ-linolenic acid (DGLA), it is C20:3n-6, and for γ-
linolenic acid (GLA), it is C18:3n-6 (Figures 35 B) (Desbois and Lawlor, 2013). 


















Figure 35:A) Structure of common PUFAs in bacteria the Image adapted from (Hayashi et al., 2016). 
B) Structure of GLA and DGLA this picture taken from (Desbois and Lawlor, 2013). 
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5.1.1 Biosynthesis of polyunsaturated fatty acids in bacteria 
There are two biosynthetic pathways are used in the production of PUFAs: 
 The first pathway is the aerobic desaturase or elongase pathway that is prevalent in 
fungi, plants, bacteria and microalgae. It involves desaturase and elongase enzymes 
that catalyse reactions in oleic acid (C18:1 ω9) (Hayashi et al. 2016). PUFAs as a 
result of several desaturation cycles of oleic acid. DHA, EPA, and ARA are also 
known as long-chain PUFAs (LC-PUFAs) that are synthesised in eukaryotes and 
prokaryotes. Thus, the aerobic pathway for synthesising LC-PUFAs is based on 
desaturation and elongation (Hayashi et al. 2016). 
The second pathway is the anaerobic PUFA synthase pathway is found in bacteria and 
eukaryotic microalgae. This pathway comprises PUFA synthases that use acetyl CoA 
and malonyl-CoA as the beginning and extender entities in the biosynthesis of PUFAs 









Figure 36: Biosynthesis of PUFA in bacteria, the picture taken from (Hayashi et al. 2016). 
 
Long-chain PUFAs (LC-PUFAs) encompasses all PUFAs with 18 to 20 or more 
carbon atoms in their chains (Abedi and Sahari, 2014). The biosynthesis of LC-PUFAs 
in bacteria involves 3 main stages of initiation, extension and chain termination 
(Figure 37). At the initiation stage of biosynthesis of LC-PUFAs, the activation of the 
acyl-carrier proteins (ACPs) from their dormant forms is observed. 
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Phosphopantetheinase (PPTase) is a catalyst in this process. The next step is an 
extension process that consists of the elongation, formation of double bonds, and the 
generation of the structure of the final product. The activated ACP accepts acetyl and 
malonyl groups from acetyl-CoA and malonyl-CoA in reactions catalysed by 
acyltransferase (AT) and malonyl-CoA acyltransferase (MAT) (Figure 37) (Yoshida 
et al. 2016). The final stage of the biosynthesis of LC-PUFA is the incorporation of 













Figure 37: The Biosynthesis of LC-PUFAs in bacteria, the picture taken from (Yoshida et al. 2016). 
 
5.1.2 Biological role of polyunsaturated fatty acids in bacteria 
Normally, PUFAs are implicated in the adaptation of bacterial cells to osmotic stress. 
PUFAs in the membranes of bacterial cells play the same roles as in other organisms 
with the focus on guaranteeing the survival through energy storage (Yoshida et al. 
2016). 
According to (Elrazak and Glassey 2013) PUFAs are important for “modulating the 
architecture, dynamics, phase transition, and permeability of membranes and the 
cohesion of membrane-associated processes.” PUFAs guarantee the selective 
permeability of membranes in cells in prokaryotes, as well as their significant 
Chapter 5: Polyunsaturated fatty acid gene clusters regulated by sco0110 
81 
 
flexibility. Moreover, membrane-bound proteins are also regulated with the help of 
PUFAs.  
The function of LC-PUFAs such as EPA, ARA and DHA is that they play a part in the 
resilience of bacteria against oxidising agents such as hydrogen peroxide (Fu et al., 
2015, Yoshida et al., 2016). It has also been reported that EPA plays a role in the 
development of bacteria in conditions of low temperatures and high pressures, 
particularly in Shewanella species and EPA ensures the structural integrity of cells by 
influencing the extent of hydration and promotes cell division at elevated pressures. 
In addition (Yoshida et al. 2016, p. 10). 
 
5.1.3 Antibiotic activity of polyunsaturated fatty acids in bacteria 
LC-PUFAs have well-known antimicrobial and anti-inflammatory properties 
associated with preventing the growth of pathogenic microorganisms. As a result, LC-
PUFAs are used in topical therapies for Gram-positive contagions infection. The 
antimicrobial properties of EPA, DHA, GLA, DGLA and 15-hydroxyeicosatrienoic 
were tested against Staphylococcus aureus and Propionibacterium acnes. The LC-
PUFAs were shown to prevent the growth of the bacteria at minimum inhibitory 
concentrations ranging from 32 to 1024 mg/L (Desbois & Lawlor 2013). The LC-
PUFAs inhibited the growth of P. acnes and demonstrated bactericidal properties on 
S. aureus only. S. aureus cells were killed within 15 to 30 minutes following exposure 
to the LC-PUFAs (Desbois & Lawlor 2013).   
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 Bioinformatics analysis for polyunsaturated fatty acid 
gene clusters regulated by sco0110 
S. coelicolor has 16 proteins highly similar to sco0110 shown in (Table 1) each of 
them responsible for controlling different pathways (Xu et al., 2012), the SCO0110 
may be involved in promoting biosynthesis of polyunsaturated fatty acid. 
Bioinformatic analysis helped to identify the polyunsaturated fatty acids which are due 
to secondary metabolite gene cluster in S. coelicolor.  
As explained in section 1.5, antiSMASH and BLAST can be used to proposed function 
of gene clusters.  This was done for the sco0110 gene as well.  
Tools to do this antiSMASH (http://antismash.secondarymetabolites.org/). (Figure 38 
A & B). ). AntiSMASH successfully identified a polyunsaturated fatty acid 
biosynthetic gene cluster in S. coelicolor (Figure 39). In addition, it is useful for novel 
natural products discovery and bioinformatics tools such as the National Centre for 
Biotechnology Information (NCBI) BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
and useful to identify Proposed function for all this genes of  polyunsaturated fatty 
acid metabolite gene clusters in (Table 21). The SCO0110 protein is found in 
Streptomyces coelicolor A3(2). It is a proposed pathway specific transcriptional 




























Figure 39: Proposed the polyunsaturated fatty acid genes cluster contain 42 genes. 
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Table 21: Proposed function of the biosynthetic genes from the sco0110 cluster. 
Genes Protein 
(number of aa) 
GenBank 
Homologue (% 

























279 aa             
DNA-binding protein  
(37% /51%) mmyB 






















No protein  
 pseudo 
sco0114 AL939104.1 





regulator, TetR family 
(99%/100%) 









































































































2240 aa  
MULTISPECIES: type 
I polyketide synthase 
(99%/99%) 
Streptomyces sp  
WP_038535457.1 
Type I polyketide 
synthase 














sco0129 WP_011026870.1   
124 aa   
Hypothetical protein  
99%/ 99% 
Streptomyces lividans  








































hypothetical protein  
98%/100% 




















































Nuclear transport factor 
















































sco0145 WP_011026882.1   
342 aa 






sco0146 Unknown   Pseudo 
Chapter 5: Polyunsaturated fatty acid gene clusters regulated by sco0110 
88 
 
sco0147 WP_011026883.1   
163 aa 
DUF2975 domain-
containing protein  
99%/100% 





 Overexpression sco0110 gene from S. coelicolor M145 
 
SCO0110 protein is found in Streptomyces coelicolor A3(2). It is a proposed to be a 
transcriptional activator for the polyunsaturated fatty acid biosynthetic gene cluster. 
The polyunsaturated fatty acid biosynthetic gene cluster is tightly regulated at the 
transcriptional level, and is usually not produced and if it is produced, then it is 
produced in a very small quantity in laboratory growth conditions 
Overexpression of transcriptional activators under the control of ermEp* is expected 
to unlock the production of compounds from neighbouring cryptic biosynthetic gene 
clusters. To investigate this, an experiment is performed in which if overexpression of 
this activator will switch on the polyunsaturated fatty acid biosynthetic genes cluster 
and express other sco gene to produce the polyunsaturated fatty acid illustrated in 
Figure 39. To this end, it is very important to clone the sco0110 gene in the pOSV556 
vector (which has the ermEp* promotor) and then introduce it into S. coelicolor m145. 
In order to do this, PCR was used to amplify specific the sco0110 gene. Two primers 
were designed (sco0110 forward and reverse) (T02 in Table 4). PCR products were 
run on 1% agarose gel in order to verify the size of the construct which yields a band 
at the expected 840 bps (Figure 40 A). A NanoDrop ND-1000 spectrophotometer was 
used to measure the concentration of the mmyB construct (109.4 ng/ μl). 
Digestion and ligation of plasmid pOSV556 followed by insertion of sco0110 were 
performed as part of cloning and plasmid analysis. The plasmid created by this ligation 
is known as pVN3 (containing sco0110 under the control of ermEp*). Plasmid DNA 
was amplified in E.coli Top10 strain and purified using the mini-prep procedure; the 
agarose gel run following the mini-prep of the construct is shown in Figure 40 B. This 
construct was then ready to transform into non-methylation E. coli ET12567/pUZ8002 
host cell (by electroporation) to introduce into S. coelicolor M145. 
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The S. coelicolor M145 already contains a methyl-sensing restriction system (MacNeil 
et al., 1992). 









Figure 40: A) PCR was used to amplify sco0110. This reaction solution was run on 1% agarose gel in 
order to verify the size of the expected band, at around 840 bps (Track 1) compared to a FastRuler 
middle range DNA ladder (Track L). B) Schematic map for the sco0110 ligated into pOSV556which 
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 Screen of the vector via a PCR amplification 
PCR screening was used to amplify the sco0110 target sequence of gene using two 
primers (primers number T02 in Table 4). PCR products were run on 1% agarose 
gel in order to verify the size of the expected band which was 840 bps (Figure 41). At 
this stage, the DNA construct after cloning was sent for sequencing analysis to verify 
that no mutations had taken place during the cloning steps and this was confirmed in 












Figure 41: Assessment of the pVN3 by doing PCR amplification used tow primers. This was then run 
on a 1% agarose gel in order to check the size of the expected band. FastRuler high range DNA ladder 
(Track L). The sco0110 insert around 840 bps and vector is 9009 bps (Track 1). The pOSV556 band 
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 Assessment of the pVN3 in S. coelicolor M145 using 
genomic DNA extraction and PCR screening  
 
To introduce the pVN3 plasmid into S. coelicolor M145, non-methylation E. coli 
ET12567/pUZ8002 host cells (by electroporation) were required to transfer the 
plasmid using intergenic conjugation, this is because S. coelicolor M145 contains a 
methyl-sensing restriction system. The construct was successfully introduced through 
conjugation in S. coelicolor M145. After genomic DNA extraction of pVN3, which 
was integrated into S. coelicolor M145, a concentration of 211.9 ng/µl for the purified 
plasmid was obtained. PCR screening was used to amplify the DNA target sequence 
of the gene using two designed primers. The PCR products were run on 1% agarose 
gel and observed a single band around the expected size of 840 bps (Figure 42). Once 
screened, this plasmid was transferred into S. coelicolor M145 via conjugation.  
Using intergenic conjugation, we were hence able to successfully integrate the 









Figure 42: Assessment of the genomic DNA by using PCR amplification for pVN3 integrated in S. 
coelicolor M145 after genomic DNA extraction technique (Track 1). FastRuler high range DNA ladder 
(Track L). Positive control used sco0110 ligated pOSV556 (Track 2). S. coelicolor M145 only was used 
as negative control (Track 3). 
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 Transcription analysis of the poly unsaturated fatty 
acid biosynthetic gene through RT-PCR 
To find the expression-specific pathway after overproduction of pVN3 integrated in 
S. coelicolor, reverse transcription-PCR was performed on the extracted total RNA 
from pVN3 integrated into S. coelicolor M145 and wild type S. coelicolor M145.  
Total RNA was extracted from S. coelicolor M145 strain in which pJT1 was integrated 
into. Three expected bands representing intact ribosomal RNA were observed with the 
total RNA concentration of 129 ng/ µl. RNA products were run on 1% agarose gel (in 








Figure 43: Total RNA was extracted from S. coelicolor M145 grow in MMS.  This reaction solution 
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5.6.1 Transcription analysis by RT-PCR for sco0108, 0110, 0117, 
0124, and sco0127 
 
The RNA was converted into single stranded complementary DNA (cDNA) by using 
cDNA Superscript II RT. As a control, a sample with no reverse transcriptase used to 
ensure that the results observed are that of the amplification of cDNA and not DNA 
contamination. The cDNA synthesised were used as a template in thermal cycler 
reactions to determine if sco0110 gene was transcribed. PCR products were run on 1% 









Figure 44: Analysis of the expression of a selection sco genes sco0108, 0110.0117, 0124 and sco0127in 
S. coelicolor M145/ pVN3 using RT-PCR using as a control primers designed to amplify the hrdB gene 
considered to be constitutively expressed (Track 1). The negative control was performed using S. 
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 Bacterial growth conditions and antibiotic assay 
5.7.1 S. coelicolor M145 with and without pVN3 growth conditions   
 
In order to confirm that the construct has been incorporated in S. coelicolor, the 
pOSV556 vector containing the cloned sco0110 gene (pVN3) was transferred to 
Streptomyces coelicolor M145 by intergenic conjugation according to standard 
methods by (Kieser, 2000), then keep it in incubation at 30 oC for 6 days to allow 
growth of the exconjugants in SFM agar (Figure 45). It was observed that the plate 
with integrated overproduction with pJT1 shows growth and produced dark blue 
pigments (plate 2 Figure 56). However the wild type shows white colony. From this it 
can be concluded that after integration of the pJT1 plasmid, it was able to switch on 
the silent pathway and produced lantibiotic antibiotics. However, in the wild type, this 










Figure 45: Culture S. coelicolor M145 after growth 6 days at 30 oC which contain the plasmid pVN3 
was integrated into S. coelicolor M145 (plate 2), S. coelicolor M145 growth without integrated pVN3 
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5.7.2 Antibiotic assay 
 
In order to confirm that after integration of the pVN3 plasmid, it was able to switch 
on the silent pathway and produced polyunsaturated fatty acids antibiotics. All the five 
genes sco0108, sco0110, sco0117, sco0124, sco0127) were expressed when the 
sco0110 was integrated in S. coelicolor M145. Antimicrobial activity of S. coelicolor 
M145/ pVN3 was test using antibiotic sensitivity assay. The antibiotic sensitivity 
assay shows the ability of drug in inhibition zone for the growth of the bacteria 
Bacillus subtilis S. aureus but not active around the E. coli (Figure 46). The positive 
control was Apramycin Track 2, the antibiotic drug of the plasmid pJh2 was integrated 
into S. coelicolor W81 and metabolites were tested after organic extraction showing 
zone of inhibition (Track 1). Hence it can be deduced that methylenomycin antibiotic 
are produced. 
  
























Figure 46: Antibiotic assay used Bacillus subtilis, E. coli and S. aureus on LB agar pH 5. The plasmid 
PVN3 was integrated into S. coelicolor M145 and metabolites were tested without organic extraction 
showing zone inhibition but not active around the E. coli (Track 1). Apramycin used as positive control 
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5.7.3 Identification of predicted lantibiotic compounds in S. 
coelicolor M145 heterologous hosts 
 
Metabolites between the S. coelicolor with pVN3 heterologous host strains and S. 
coelicolor M145 wild type were compared by LC-MS and one new compound was 
identified. The m/z= 1475 was only present in S. coelicolor strains containing pVN3 
and was absent in S. coelicolor M145 control (Figure 47). 
 
Figure 47: UV chromatogram the predicted antibiotic compound. Extracted ion chromatograms m/z 










M145 dSCO0110_4944.d: EIC (1475.00; 1477.00)±0.1 +All MS M145_BA2_01_4943.d: EIC (1475.00; 1477.00)±0.1 +All MS
1476.93
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 Combined antibiotic activity 
This section explores the combined antibiotic activity of novel S. coelicolor 
compounds against B. subtilis and S. aureus. Antimicrobial activity of S. coelicolor 
M145/pVN3, pJT1 and S. coelicolor W81/pJH2 was cultured in Smm broth Figure 
50 then tested using antibiotic sensitivity assay. The new compounds produced by S. 
coelicolor engineered strains was assayed against B. subtilis and S. aureus. The 
antibiotic sensitivity assay shows the ability of the antibiotics produced from a 
combination of these strains shows that there is a large drug inhibition zone which 
does not allow B. subtilis and S. aureus to grow. The overexpression of mmyB and 
mmyB-like genes together can turn on silent biosynthetic pathways, this novel strategy 
results in the overproduction and discovery of new natural products can be observed 
(Figure 48 and 49). LC-MS need to be performed on the metabolites to find the new 












Figure 48: Culture S. coelicolor engineered strained (pJH2, pJT1 and PNV3) shows in MMS media 
dark blue Track 1. However the colour for wild type which was include both S. coelicolor W81/M145 
has brown colour Track 2. 
1 2 























Figure 49: Antibiotic assay used Bacillus subtilis and Staph aureus on LB agar pH5. S. coelicolor 
engineered strained (pJH2, pJT1 and PNV3) metabolites were tested without organic extraction 
showing zone inhibition (Track 1). Apramycin used as positive control (Trach 2), S. coelicolor 
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By culturing the following: 
1- S. coelicolor M145/ pVN3 
2- S. coelicolor M145/pJT1  
3- S. coelicolor W81/pJH2 
S. coelicolor engineered strains were tested individually using antibiotic sensitivity 
assay. The new compounds produced by S. coelicolor engineered strains have been 
assayed against B. subtilis. The results show each compound that is produced from S. 
coelicolor engineered strains kills B. subtilis (Figure 50 A).  
On the other hand, while mixing an equal amount 15 µL of S. coelicolor M145/ pVN3 
with 15ml of S. coelicolor M145/pJT1, shows that the combination of the two S. 
coelicolor engineered strains was not active against B. subtilis and S. aureus. Also 
mixing another equal amount of either S. coelicolor M145/ pVN3 with S. coelicolor 
W81/pJH2 or mixing an equal amount of both S. coelicolor W81/pJH2 with S. 
coelicolor M145/pJT1 will still shows no activity against B. subtilis and S. aureus. 
Furthermore mixing all three S. coelicolor engineered strains, M145/ pVN3, 
M145/pJT1 and W81/pJH2 will still show no zones inhibition on the agar overlay plate 
(Figure 50 B). 










Figure 50: Antibiotic assay used Bacillus subtilis on LB agar pH5. S. coelicolor engineered strained 
(pJH2, pJT1 and PNV3) individually metabolites were tested without organic extraction individual was 
active zone inhibition against B. subtilis. However, while mixing an equal amount each of them 15 µL 
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6 Chapter 6 Other mmyB-like protein  
 
S. coelicolor has 16 proteins high similar to MmyB shown in (Table 1) . While 16 
mmyB-like homologues are encoded within S. coelicolor each of them responsible for 
controlling different pathways some of the  divergent proposed gene regulated show 
in the Table 22. 
Table 22: sco all are putative DNA-binding protein 
Divergent proposed 
gene regulated  


















sco0104-sco0149 Polyunstaturated fatty 
acid biosynthesis 
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sco7768 – sco7769 Nuclear transport factor 
2-like protein, similar to 
RANGDPbinding; fused 
to gene for GDPsugar 
epimerase 












The proteins high similar to MmyB Some of them as shown in Table 23 successfully 
constructed after that introduce the mmyB-like gene in similar vectors into S. 
coelicolor using inter-generic conjugation then to assess the antibiotic assay after 
integrated mmyB-like in S, coelicolor which show after overexpression transctrapital 
activoter able to switch on gene clusters to produce natural products with mutant strain 
which inhipit growth Bacillus subtilis. E. coli and S. aureus except sco0236 and 
sco0891 were find this not active antibiotic activity see more details in appendix 
section.  
All this test need more investigation to find the gene cluster by using AntiSmash for 
each mmyB-like. In additional, RT-PCR used to detection express gene cluster and by 
using chemical analysis for more identifications process. 













sco0236 Done  Non active     Not done  
sco0891  Done  Not done  Not done  
sco7140 Done  Active  Not done  
sco4680 Done  Active   Not done  
sco7767 Done  Active   Not done  
sco7817 Done  Active   Not done  
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 Other mmyB-like transcriptional activators cloned 
under the control of a Streptomyces constitutive 
promoter 
The same approach was used and the result as follow: 
6.1.1 SCO0236 
6.1.1.1 Cloning of sco0236  
 











Figure 51:A)  PCR was used to amplify sco0236 this reaction solution was run on 1% agarose gel in 
order to verify the size of the expected band 872 bps (Track 1) compared to a FastRuler middle range 
DNA ladder (Track L). B) Schematic map for the sco0236 ligated into pOSCV556 which has been 














6.1.1.2 Assessment of the pWAL3 in S. coelicolor M145 using genomic DNA 













Figure 52: Assessment of the genomic DNA by using PCR screen for pWA3 integrated in S. coelicolor 
M145 after genomic DNA extraction technique (Track 1). FastRuler middle range DNA ladder (Track 
L). Positive control used cos0236 ligated pOSV556 (Track 2). S. coelicolor M145 only was used as 
negative control (Track 3). 
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6.1.1.3 Bacterial growth conditions and antibiotic 
 














Figure 53: Culture S. coelicolor M145 after growth 6 days at 30 oC which contain the plasmid pWAL3 
was integrated into S. coelicolor M145. 
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Figure 54: Antibiotic assay used Bacillus subtilis and E. coli on LB agar pH 5. The plasmid PWAL3 
was integrated into S. coelicolor M145 and metabolites were tested and showing not inhibit growth of 
bacteria (Track 1). Apramycin used as positive control (Trach 2), S. coelicolor M145 only without the 













The same approach was used and the result as follow: 
6.1.2.1 Cloning of sco7140 
 








Figure 55: A) PCR was used to amplify sco7140. This reaction solution was run on 1% agarose gel in 
order to verify the size of the expected band, at around 831 bps (Track 1) compared to a FastRuler 
middle range DNA ladder (Track L). B) Schematic map for the sco7140 ligated into pOSV556 which 
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Figure 56: Assessment of the DNA fragment size. The purified DNA construct was ligated into 
pOSV556 vector and was digested using the restriction enzyme HindIII and PstI. This was then run on 
a 1% agarose gel in order to chick the size of the expected bands. FastRuler high range DNA ladder 
(Track L), the size of the excised the sco7140 insert around 831 bps and vector is 9009 bps (Track 2). 
A positive control was used pOSV556 vector and was digested using the restriction enzyme HindIII 
(Track3) and the sco7140 gene produced from the PCR reaction (Track 4).  
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6.1.2.3 Assessment of the pHAM3 in S. coelicolor M145 using genomic DNA 













Figure 57: Assessment of the genomic DNA by using PCR screen for pHAM3 integrated in S. 
coelicolor M145 after genomic DNA extraction technique (Track 1). FastRuler high range DNA ladder 
(Track L). Positive control used sco7140 ligated pOSV556 (Track 2). S. coelicolor M145 only was used 
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6.1.2.4 Bacterial growth conditions and antibiotic 
 












Figure 58: culture S. coelicolor M145 after growth 6 days at 30 oC which contain the plasmid pHAM3 
was integrated into S. coelicolor M145. 
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Figure 59: Antibiotic assay used Bacillus subtilis on LB agar pH 5. The plasmid pHAM3 was integrated 
into S. coelicolor M145 and metabolites were tested and showing zone inhibition (Track 1). Apramycin 
used as positive control (Trach 2), S. coelicolor M145 only without the pHAM3 was used as negative 













The same approach was used and the result as follow:  
6.1.3.1 Cloning of sco7706 
 










Figure 60: A) PCR was used to amplify sco7706 this reaction solution was run on 1% agarose gel in 
order to verify the size of the expected band, at around 855 bps (Track 1) compared to a FastRuler 
middle range DNA ladder (Track L). B) Schematic map for the sco7706 ligated into pOSV556 which 
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Figure 61: Assessment of the sco7706 frament size by doing PCRAssessment of the sco0236 fragment 
size by doing PCR amplification used tow primers. This was then run on a 1% agarose gel in order to 
check the size of the expected band. FastRuler high range DNA ladder (Track L). The sco0236 insert 
around 840 bps and vector is 9009 bps (Track 2&3). The pOSV556 band around 9009 bps as positive 
control (Track 1). Positive control was used sco0236 gene (Track 3).  




6.1.3.3 Assessment of the pNBH3 in S. coelicolor M145 using genomic DNA 










Figure 62: Assessment of the genomic DNA by using PCR screen for pNBH3 integrated in S. 
coelicolor M145 after genomic DNA extraction technique (Track 1). FastRuler high range DNA ladder 
(Track L). Positive control used sco7706 ligated pOSV556 (Track 2). S. coelicolor M145 only was used 
as negative control (Track 3). 
6.1.3.4 Bacterial growth conditions and antibiotic 
 












Figure 63: culture S. coelicolor M145 after growth 6 days at 30 oC which contain the plasmid pNBH3 
was integrated into S. coelicolor M145. 
                     L                                    1                  2                    3 
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6.1.3.4.2 Antibiotic assay 
 
Antimicrobial activity of S. coelicolor M145/ pNBH3 was test using antibiotic 
sensitivity assay. The antibiotic sensitivity assay shows the ability of drug in inhibiting 
























Figure 64: Antibiotic assay used Bacillus subtilis E. coli and S. aureus on LB agar pH 5. The plasmid 
pNBH3 was integrated into S. coelicolor M145 and metabolites were tested and showing zone inhibition 
both Bacillus subtilis and S. aureus (Track 1). Apramycin used as positive control (Trach 2), S. 















The same approach was used and the result as follow: 
6.1.4.1 Cloning of sco7817 
 








Figure 65: PCR was used to amplify sco8717. This reaction solution was run on 1% agarose gel in 
order to verify the size of the expected band, at around 843 bps (Track 1) compared to a FastRuler 
middle range DNA ladder (Track L). B) Schematic map for the sco7817 ligated into pOSV556 which 
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Figure 66: Assessment of the sco7817 fragment size by doing PCR amplification used tow primers. 
This was then run on a 1% agarose gel in order to check the size of the expected band. FastRuler high 
range DNA ladder (Track L). The sco7817 insert around 840 bps and vector is 9009 bps (Track 1). The 
pOSV556 band around 9009 bps as positive control (Track 2). Positive control was used sco7817 gene 
(Track 3). 
6.1.4.3 Assessment of the pAMR3 in S. coelicolor M145 using genomic DNA 











Figure 67: Assessment of the genomic DNA by using PCR screen for pAMR3 integrated in S. coelicolor 
M145 after genomic DNA extraction technique (Track 1). FastRuler middle range DNA ladder (Track 
L). Positive control used sco7817 ligated pOSV556 (Track 2). S. coelicolor M145 only was used as 
negative control (Track 3). 
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10000 bps  
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6.1.4.4 Bacterial growth conditions and antibiotic 
 
6.1.4.4.1 S. coelicolor M145 with and without pNB3 growth conditions   
 
The pOSV556 vector containing the cloned sco7817 gene (pAMR3) was transferred 
to S. coelicolor M145 by intergenic conjugation according to standard methods by 
(Kieser, 2000) with some modification. Overlay the plate with 1 mL sterile distilled 
water containing 20 µL nalidixic acid (from 25 mg/mL stock) to kill E. coli, 25 µL of 
100 mg/mL stock ampicillin and 25 µL of 50 mg/mL stock hygromycin to select the 
Streptomyces exconjugants. Then keep it in incubation at 30 oC for 6 days to allow 











Figure 68: culture S. coelicolor M145 after growth 6 days at 30 oC which contain the plasmid pAMR3 
was integrated into S. coelicolor M145.  
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6.1.4.4.2 Antibiotic assay 
 
Antimicrobial activity of S. coelicolor M145/ pAMR3 was test using antibiotic 
sensitivity assay. The antibiotic sensitivity assay shows the ability of drug in inhibiting 























Figure 69: Antibiotic assay used Bacillus subtilis, E. coli and S. aureus on LB agar pH 5. The plasmid 
pAMR3 was integrated into S. coelicolor M145 and metabolites were tested and showing zone 
inhibition (Track 1). Apramycin used as positive control (Trach 2), S. coelicolor M145 only without 










Chapter 7: Final discussion and future work 
121 
 
7 Chapter 7: Final discussion and future work 
 
Despite the success and discovery of approaches for natural product synthesis, there 
is still a need for novel antimicrobial agents because of the rise in multi-drug resistance 
microorganisms. In addition, the increase and spread of multidrug-resistant pathogens 
have become a growing threat to global common health. 
The soil bacteria of the genus Streptomyces are a rich source of bioactive secondary 
metabolites. It contains dozens of gene clusters involved in the direct biosynthesis of 
specialised metabolites. Many gene clusters for natural product are cryptic and silent, 
they are produced in very small quantities or not activated under laboratory culture 
conditions (Bentley et al., 2002, Zerikly and Challis, 2009). 
Streptomyces coelicolor A3(2) are the largest genus of Actinobacteria and are a rich 
source of antibiotics and bioactive secondary metabolites which may become suitable 
for human, veterinary medicine and agricultural applications (Genilloud, 2017). 
Streptomyces species are a good source for commercially viable antibiotics; (Kieser, 
2000, Procopio et al., 2012, Ventura et al., 2007). 
Streptomyces coelicolor A3(2) is widely used as a model organism to study the 
bacterial genome. When the genome was first sequenced, it identified many pathways 
with unknown natural products that might not be expressed in laboratory conditions 
and may need to be further investigated (Bentley et al., 2002). The metabolites are 
synthesised from biosynthetic gene clusters (BGCs): genes which typically remain 
silent unless stimulated. These clusters need very specific environmental conditions 
(such as pH, temperature and/or a specific nutrient) or physiological stimuli like 
inducer molecules to switch on so as to be able to produce natural products (Harrison 
and Studholme, 2014). Gene expression in S. coelicolor is tightly regulated and it has 
the genetic capability to produce natural products in a laboratory environment.(Bibb, 
2005, Gottelt et al., 2010, van Wezel and McDowall, 2011). 
It is very important for bacteria to regulate the production of antibiotics to prevent 
toxic stress on the producer strain which could subsequently lead to cell death (Ramos 
et al., 2005). Streptomyces regulatory systems often include both transcriptional 
activators and repressors to control the production of the secondary metabolites (Aigle 
and Corre, 2012). However, this is not always the case. For example, S. venezuelae 
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has a gaburedin biosynthetic gene cluster which does not have any transcriptional 
activators. Instead, it can de-repressed by the inactivation of the gbnR repressor 
(sven_4187) which leads to the upregulations of gaburedins (Sidda et al., 2014). 
However, many Streptomyces genomes contain one or more gene coding for a putative 
TetR repressor (Cuthbertson and Nodwell, 2013). 
Recent research in the field has focussed on the genetic manipulation of Streptomyces 
in order to awaken silent cryptic clusters. BGCs can be unsilenced by genetic 
engineering via overexpression of pathway specific activators or disruption of 
pathway specific repressors (Aigle and Corre, 2012). 
A method for awakening silent cryptic BGCs involved in activation of transcriptional 
repressors that bind to specific nucleotide sequences in operator region. These 
repressors inhibit expression of their own gene as well as indirectly repressing other 
gene as a result (Aigle and Corre, 2012). 
Previous studies have primarily focussed on the deletion or inactivation of TetR-like 
transcriptional repressors to switch on the silent biosynthetic gene clusters; for 
example,  
1. Deleting the gene arpA repressor in the S. griseus genome leads to the 
overproduction of streptomycin which can also develop aerial hyphae earlier 
than the wild type strain (Kato et al., 2004).  
2. Deleting the gene mmR repressor into the S. coelicolor leads to the 
overproduction of methylenomycin. (Aigle and Corre, 2012). 
3. Deletion of the scbR2 repressor gene into the S. coelicolor leads to the 
overproduction of the yellow pigment coelimycin (Gomez-Escribano et al., 
2012).  
4. Deletion of the gbnR repressor gene into the S. venezuelae leads to the 
overproduction of the gaburedins (Sidda et al., 2014). 
  
The aforementioned examples confirm that the deletion of transcriptional repressors 
is a powerful strategy for the discovery of natural products and the identification of 
silent cryptic biosynthetic gene clusters. 
Chapter 7: Final discussion and future work 
123 
 
In contrast, the genes in the biosynthetic pathway of interest may be targeted to switch 
on the ‘silent’ pathways. This allows the determination of cryptic natural products by 
overexpression of transcriptional activators. 
In Streptomyces coelicolor, the bioactive secondary metabolites gene clusters often 
include regulatory genes controlling the production of that natural product. For 
example, genes actII-orf4, red and mmyB all encode for transcriptional activators 
which are found within the gene clusters for the biosynthesis of actinorhodin, 
streptorubin B and methylenomycin, respectively in S. coelicolor. Therefore, specific 
regulatory elements in the biosynthetic pathway of interest may be targeted in order to 
turn on potentially silent pathways and to determine the nature of the corresponding 
cryptic natural product. 
The first method for awakening a silent cryptic BGCs to discover novel metabolites in 
Streptomyces involves overexpression of the ultimate activator to induce natural 
production. An example of this is the silent type I PKS gene cluster ATCC23877 in S. 
ambofaciens, which when activated results in the synthesis of macrolide compounds 
named the Stambomycins. Stambomycins are biosynthesised by a silent PKS gene 
cluster. The regulatory gene samR0484, encoding a positive LAL regulator was 
selected for overexpression and cloned into a conjugative and integrative plasmid 
(pIB139) which is under the control of the strong constitutive promoter ermE*p 
(derivative named pOE-0484). This was then transformed into E. coli 
ET12567/pUZ8002 followed by transfer into a Streptomyces host through intergenic 
conjugation: a wild type strain and a mutant strain with presence of pOE-0484 led to 
unlocked the production of the stambomycins which were silent in the wild type strain 
(Laureti et al., 2011). 
Methylenomycin is one of very few known antibiotics in which the whole biosynthetic 
cluster is entirely plasmid based. Methylenomycin gene cluster is found on a 19 kb 
region in the S. coelicolor SCP1 plasmid and has 21 biosynthetic genes clusters 
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Methylenomycin biosynthesis is strongly regulated by different mechanisms including 
1. those that are through transcriptional activators,  
2. those mechanisms which rely on the influence of the presence (and absence) 
of the methylenomycin furans and transcriptional repressors (O'Rourke et al., 
2009). 
The original aims of this study were: 
A. To clone mmyB and a series of S. coelicolor mmyB-like pathway-specific 
transcriptional activators under the control of a Streptomyces constitutive 
promoter. 
B. To introduce these vectors, using intergenic conjugation in Streptomyces 
coelicolor strain. 
C. To analyse the expression profile of mmyB-like genes and that of putative 
biosynthetic genes located next to the mmyB-like regulatory genes using RT-
PCR. 
D. To test the antibiotic activity of metabolic extracts where mmyB-like genes 
have been overexpressed versus negative controls. 
E. Collaboration with a colleague to compare the metabolic profiles of the 
engineered Streptomyces strain using LC-MS analyses and compounds of 
interest (metabolites produced) that are normally detected by using High-
Pressure Liquid Chromatography (HPLC) and possibly isolate and elucidate 
the structure of novel antimicrobials using additional analytical chemistry 
techniques (mass spectrometry and NMR spectroscopy). However, time 
constraints did not allow for HPLC and NMR experiments to be performed.  
The objective of this study was to clone mmyB and a series of mmyB-like pathway-
specific transcriptional activators under the control of Streptomyces constitutive 
promoter (ErmE*p promoter) in E.coli / Streptomyces shuttle vector. This novel 
approach will allow the organism to express silent biosynthetic gene clusters. 
Resultantly, more of the natural products can be extracted from bacteria which would 
otherwise have not been possible.  
We were able to achieve aims A,B,C,D, but E could not be completed. The first step 
taken was to clone the mmyB or mmyB-like cluster-associated transcriptional vector 
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into the integrative vector pOSV556. This was done using intergenic conjugation by 
designing a specific vector for introduction into the Streptomyces genome. 
Overexpression of transcriptional activators such as mmyB and mmyB-like were found 
to be products of cryptic biosynthetic gene clusters which are activated by switching 
on the production of compounds from neighbouring cryptic biosynthetic gene clusters. 
This was done homologously in S. coelicolor. There were a series of activators that 
belong to pathway-specific regulators which are MmyB-like. There are 16 mmyB-like 
homologues which are encoded within S. coelicolor (Xu et al., 2012). Overexpression 
of some of these activators resulted in the production of novel lantibiotic and 
polyunsaturated fatty acids (unpublished).  
Methylenomycin gene cluster contains 21 genes (19 kb). The mmyB gene is found in 
S. coelicolor A3 (2) gene cluster located in the linear chromosome called SCP1 (365 
000 bps). Based on the genetic organization, the mmyB gene is proposed to be a 
transcriptional activator for the methylenomycin biosynthetic gene cluster. Expression 
of mmyB is normally repressed by TetR-like transcriptional repressor MmfR and 
MmyR, bound upstream of its promoter at the Methylenomycin Auto-Regulatory 
Element (MARE). Both MmyR and MmfR have been shown to bind to the promoter 
region of mmyB. Furan ligands (MMFs) can bind and make conformational change to 
MmfR. MmfR by releasing them from the MARE sequence and hence allowing the 
expression of mmyB. The DNA-binding protein MmyB can then bind to B-boxes and 
recruit RNA polymerase thus activating the expression of antibiotic-like biosynthetic 
genes  (O'Rourke et al., 2009).  
In this project, the cloning sequence for i) mmyB, and mmyB-like such as ii) sco6926, 
and iii) sco0110 were successfully amplified and ligated with vector pOSV556 (under 
the regulation of ermEp*). The new plasmids were named pJH2, pJT1 and pVN3 
respectively. All the ligations were assessed through PCR and verified by DNA 
sequencing: forward and reverse sequencing confirms the cloning of mmyB, sco6926 
and sco0110 with vector pOSV556. These were all successful with no errors. 
The expression plasmids for pJH2, pJT1 and pVN3 were transformed into the non-
methylated E. coli ET12567/pUZ8002 which can be used for conjugation with 
Streptomyces. There is evidence that DNA methylated by E.coli can prevent 
conjugation in S. coelicolor as the DNA is seen as foreign and removed from the 
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Streptomyces (Kieser et al., 2000, MacNeil et al., 1992). The constructs were 
integrated into the genome of Streptomyces via intergeneric conjugation, as described 
in sections 2.2.5.2. The methylenomycin antibiotic pathway has been silenced in the 
S. coelicolor strain W81. Therefore, this strain has lost the ability to make MMF 
because mmyLHP was deleted. The mmyB plasmid was transferred to S. coelicolor 
W81 and constitutive expression of the methylenomycin pathway-specific 
transcriptional activator MmyB was expected to stop the expression of 
methylenomycin. (Corre et al., 2008). Additionally, sco6926 and sco0110 were 
transferred to S. coelicolor M145 by intergenic conjugation. This integration happens 
using the phage attP site in the pOSV556 vector matches with attB site in the target 
host system which comes from an 11 kb integrative element in Streptomyces 
ambofaciens (Zhang et al., 2013) 
 
 
Figure 70: S. coelicolor W81 was deleted mmyLPH (not produce MMF), this strain was used to 
integrated pJH2 and expressed other mmy genes in some red and blue colours. 
 
In order to confirm the expression of mmy gene clusters in the S. coelicolor after 
overexpression, each strain with the plasmid encoding for the transcriptional activators 
(and a negative control) was grown on supplemented minimal medium (SMM) which 
is a simple production medium for secondary metabolites. Each of these strains were 
grown for 6 days and they were analysed by RT-PCR, antibiotic assay and  liquid 
chromatography-mass spectrometry (LCMS) analyses to confirm that the metabolites 
are overproduced in the strains containing pJH2, pJT1 and pVN3 relative to the wild 
type. Each of these will now be discussed further. 
The metabolic profile using RT-PCR of Streptomyces strains constitutively expressing 
the transcriptional activator(s) was obtained by extracting the total RNA from S. 
coelicolor W81 wild-type and from S. coelicolor W81 with integrated pJH2. These 
were grown in MMS to evaluate the expression of a range of mmyB and other genes 
within the methylenomycin gene cluster. RT-PCR was performed to give single 
stranded complementary DNA (cDNA) synthesised from the DNA of S. coelicolor 
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W81 wild-type (negative control) and from the strain with integrated pJH2. They were 
both used as a template in PCR reactions to amplify the transcribed mmyB and other 
genes within the methylenomycin genes cluster. After integration of the plasmid (i.e. 
pJH2), all eight mmy genes were expressed in the S. coelicolor W81 but not in the 
wild-type strain, thus suggesting that the regulator is a pathway-specific activator of 
the gene cluster. Expression of nearby biosynthetic has been tested and it has been 
demonstrated that the activators turn on the expression of silent gene clusters to 
produce methylenomycin antibiotics (Figure 70). Complementary DNA from wild-
type S. coelicolor W81 was used as a negative control in the PCR and same primers 
as with template (-) RT-PCR were used. The hrdB gene was used here as a positive 
control.  
In addition, RT-PCR technique was used for the detection of lantibiotic and 
polyunsaturated fatty acids after integration of the plasmid into S. coelicolor M145 
pJT1 and pVN3 respectively,  
A. All the four sco genes (sco6926, 27, 32 and sco6933 were expressed when the 
sco6926 was integrated in S. coelicolor M145. 
B. All the five sco genes (sco0108, 10, 17, 24 and sco0127) were expressed when 
the sco0110 was integrated in S. coelicolor M145. 
All sco genes were expressed in the S. coelicolor M145 but not in the wild-type strain, 
thus suggesting that the regulator is a pathway-specific activator of the gene cluster 
and expression of nearby biosynthetic has been tested and demonstrated that the 
activators turned on the expression of silent gene clusters to produce lantibiotic and 
polyunsaturated fatty acids. 
The noteworthy consequence of this is that after integration of the transcriptional 
activator, and cloning it with a strong promoter, the silent biosynthetic gene cluster for 
methylenomycin, lantibiotic and polyunsaturated fatty acids can be switched on.  
The antibiotic sensitivity assay shows the ability of drug in inhibiting the growth of 
Bacillus subtilis, S. auras and E. coli. When overexpressing transcriptional activator 
genes from S. coelicolor, the antibacterial susceptibility was tested of the crude 
extracts (or organically extracted compound in the case of pJh2) by using a volume of 
21 µl. The antibiotic activity was monitored using S. coelicolor W81/ pJh2 by using 
antibiotic sensitivity assay which involves loading a sample onto a sterile antibiotic 
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disc (6mm). The antibiotic sensitivity assay shows the ability of methylenomycin in 
inhibiting the growth of used Bacillus subtilis, S. auras and E. coli.  
Lantibotics are antibiotics which can kill other Gram-positive bacteria. On the other 
hand, the antimicrobial activity of polyunsaturated fatty acid is also well-known. By 
comparing the metabolites produced between the S. coelicolor M145 engineered 
strains (pJT1 for lantibiotic and pVN3 for polyunsaturated fatty acids) and S. 
coelicolor M145 wild type, it was found that the former produced more active 
compounds against Bacillus subtilis, S. auras. However, in the case of E. coli, none of 
the strains showed any activity.  
The active strains produced by the engineered strains required further characterisation. 
In the first instance, this was done by liquid chromatography mass spectrometry (LC-
MS).   
Various combinations of the metabolites were also tested. Surprisingly, when mixing 
an equal amount 15 µL of S. coelicolor M145/pVN3 with 15 µl of S. coelicolor 
M145/pJT1, it was observed that the combination of the two S. coelicolor engineered 
strains was not active against B. subtilis. Similarly, mixing equal amounts of either S. 
coelicolor M145/pVN3 with S. coelicolor W81/pJH2 or mixing equal amounts of both 
S. coelicolor W81/pJH2 with S. coelicolor M145/pJT1 will still show inactive results 
against B. subtilis. This probably shows an antagonism reaction has been occurred. 
(Antagonism reaction, is when two or more antibiotic join together and lose activity). 
Furthermore mixing all three S. coelicolor engineered strains, M145/pVN3, 
M145/pJT1 and W81/pJH2 will show zones of inhibition on the agar overlay plate 
against B. subtilis. Interestingly, in this case, the zone of inhibition is much larger than 
that observed for the individual sets of metabolites. The exact reason for this rise in 
activity requires further investigation. 
The LC-MS analysis of crude extracts results allowed comparison of two samples: 
metabolites produced from the engineered strains versus the wild type.  After 
overexpression of the transcription activators, peaks can be observed in the LC-MS 
spectra of pJT1 and PVN3 which can be attributed to lantibiotics and polyunsaturated 
acids respectively. For the wild type, no peak was observed. 
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The metabolites produced after overexpression of the regulatory gene pJT1 in S. 
coelicolor M145 and wild type were compared by LC-MS. Two prospective novel 
compounds were identified with m/z = 1479.21 and 1474.93. These compound have 
proposed lantibiotic activity and were only found in the engineered S. coelicolor strain 
containing pJT1 and were absent in S. coelicolor M145 control.  
Additionally, the S. coelicolor strain with overexpression of the regulatory pVN3 gene 
in the host strain and S. coelicolor M145 wild type were compared by LC-MS with 
another prospective novel compound being identified. A peak with m/z= 1476.93 was 
only present in S. coelicolor strains containing pVN3 and was absent in S. coelicolor 
M145 control.  
On the other hand, after overexpression of the regulatory gene pJH2 in S. coelicolor 
W81 and wild type the mass of the methylenomycin was not detected or identified 
using LC-MS. However, after overexpression the regulatory gene pJH2 in S. 
coelicolor W81, the RT-PCR and antibiotic activity identify methylenomycin 
antibiotic production in S. coelicolor strains containing pJH2. 
In conclusion: 
Recently, there has been an increase in the number of natural novel products 
discovered via genomics-guided approaches. This project was focused on a specific 
secondary metabolite which is produced after a biosynthetic gene cluster is activated 
by the overexpression of a transcription activator.  For example, constitutive 
overexpression of mmyB using a strong promotor (ermEp*) resulted in the production 
of compounds from neighbouring cryptic biosynthetic gene clusters which in turn 
switched on the methylenomycin biosynthetic genes cluster to produce the 
methylenomycin antibiotics. This was confirmed by successfully performing RT-PCR 
and antibiotics assays. 
Similarly overexpression sco6962 of lantibiotic and sco0110 of polyunsaturated fatty 
acid by using a strong ermEp* promoter resulted in the production of compounds from 
neighbouring cryptic biosynthetic gene clusters which subsequently switched on the 
lantibiotic and polyunsaturated fatty acid biosynthetic genes clusters to produce the 
lantibiotic and  polyunsaturated fatty acid respectively. This was confirmed by 
successfully performing RT-PCR, antibiotics assays and LC-MS. 
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Future work  
 
Initially, attempts should be made to clone other mmyB-like pathway-specific 
transcription activators such as sco0233, sco0307, sco2501, sco2537 and sco4944 
under the control of Streptomyces constitutive promoter into integrative vectors such 
as S. coelicolor M145. It would then be helpful to find the gene cluster by using 
AntiSmash for each mmyB-like transcription activator. Furthermore, it would be 
useful to analyse the expression profile of mmyB-like genes and that of putative 
biosynthetic genes located next to the mmyB-like regulatory genes using RT-PCR. 
Next, the goal would be to introduce these plasmids using intergenic conjugation in 
other Streptomyces bacteria, such as Streptomyces albus (often used as a heterologous 
host for BGC expression) so as to activate silent pathways. One of the reasons to use 
this strain is that S. albus in particular has a wide and diverse geological distribution; 
it has been isolated from environments including sponges, sea sediments and insects. 
Strains of this streptomyces have been found to harbour 48 unique BGCs, 18 of these 
BGCs have been identified which give rise to its core secondary metabolome. The 
metabolic products of 29 out of the 48 gene clusters analysed are still unidentified; 
this shows promise on the continuing search for novel compounds with desired 
biological activities, such as antibacterial and anticancer treatments (Seipke, 2015). 
The relative antimicrobial properties of the culture supernatants obtained from these 
bacterial strains should be assessed. LC-UHRMS analyses of the samples showing 
significantly improved antimicrobial properties compared to the parent strain can then 
be carried out. Differences in the metabolic profiles should be investigated and the 
molecular formulae of metabolites only appearing in the presence of the constitutively 
expressed activators can then be generated. Database searches (i.e. Reaxys) can then 
be used to reveal which newly produced compounds exhibit molecular formulae not 
previously known for a natural product. This important step aims at preventing 
antibiotic “rediscovery”. 
Compounds of interest (metabolites produced) are normally detected by using High-
Pressure Liquid Chromatography (HPLC) which compares metabolite profiles via 
ultraviolet (UV) absorption changes at specific wavelengths. Mass spectrometry 
allows deduction of a metabolite molecular formula from its m/z value and pattern of 
Chapter 7: Final discussion and future work 
131 
 
fragment ions. Structure elucidation of pure samples and novel metabolites produced 
can then be purified and characterised via high-resolution mass spectrometry, NMR 
spectroscopy, and X-ray crystallography. 
It is important to note that turning on the production of several specialised metabolic 
pathways at once in the parent strain might lead to synergistic antimicrobial properties. 
Depending on time and resources, the supernatants resulting from Streptomyces 
strains engineered with each of the 3 different transcriptional activators could also be 
combined and synergistic antimicrobial activities assessed. The mode of action and 
combination of targets hit by these “natural” mixtures of antimicrobial compounds 
could then be investigated. 
This would allow for the assessment of the antibiotic activity of the metabolites 
produced by the engineered strains against pathogenic microbes. 
The antibiotic activity of new metabolites will be assessed in liquid culture against a 
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Reverse transcription-PCR was performed on the extracted total RNA from pN3 
integrated into S. coelicolor M145 and wild type S. coelicolor M145. The RNA was 
subject into single stranded complementary DNA (cDNA) by using cDNA 
Superscript II RT. cDNA products were run on 1% agarose gel in Figure below. It 
can use the control with no reverse transcriptase added to ensure that direct result of 


















Figure:  Detection of pVN3 integrated in S. coelicolor M145 expression sco0108, sco0110, sco0117, 
sco0124 and sco0127 genes using RT-PCR (Track 1). The negative control was performed using wild 
type of S. coelicolor M145 (Track 2) and also negative control was performed using minus RT-PCR 
using same two designated primers (Track 3). In Track 4 using as a control primers designed to amplify 
the hrdB gene considered to be constitutively expressed. 
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